metformin has been researched along with Cancer of Liver in 199 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase I dose de-escalation study aimed to assess the tolerability, safety, pharmacokinetics (PK), and efficacy of sequentially decreasing doses of sorafenib in combination (SAM) with atorvastatin (A, 10 mg) and metformin (M, 500 mg BD) in patients with advanced hepatocellular carcinoma (HCC)." | 9.51 | Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). ( Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S, 2022) |
| "Emerging data suggest that statins, aspirin and metformin may protect against hepatocellular carcinoma (HCC) development." | 9.41 | Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. ( Chan, KE; Chee, D; Fu, CE; Goh, XL; Huang, DQ; Kim, BK; Lee, SW; Lim, WH; Loomba, R; Muthiah, MD; Ng, CH; Nguyen, MH; Syn, N; Tamaki, N; Tan, C; Tan, DJH; Tan, EX; Xiao, J; Yong, JN; Zeng, RW, 2023) |
| "The views regarding the associations between metformin use and hepatocellular carcinoma (HCC) among diabetes mellitus (DM) patients are divisive." | 9.22 | Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. ( Li, Q; Sui, C; Xu, H; Zhang, H, 2022) |
| "Several studies have reported that metformin can reduce the risk of hepatocellular carcinoma (HCC) in diabetes patients." | 8.91 | Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. ( Bramer, WM; Hernanda, PY; Li, J; Pan, Q; Peppelenbosch, MP; van Luijk, J, 2015) |
| "To evaluate the safety and efficacy of metformin in patients with type 2 diabetes mellitus (T2DM) and chronic hepatitis C virus (HCV) with or without cirrhosis and hepatocellular carcinoma (HCC)." | 8.89 | Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. ( Harris, K; Smith, L, 2013) |
| "The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study." | 8.31 | Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023) |
| "To investigate the impact of metformin on survival of diabetic patients following surgery for colorectal cancer (CRC)." | 8.31 | The impact of metformin on survival in diabetes patients with operable colorectal cancer: A nationwide retrospective cohort study. ( Chu, PT; Chuang, TJ; Huang, SH; Huang, WC; Wang, JH; Wu, TH, 2023) |
| "Lenvatinib is a first-line drug commonly used in the treatment of advanced hepatocellular carcinoma (HCC)." | 8.31 | Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway. ( Cen, X; Cheng, Y; Lu, J; Lu, Y; Luo, C; Wang, F; Xie, C; Yin, Z; Zhan, P, 2023) |
| "Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3, and it inhibits HCC progression." | 8.31 | Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3. ( Dong, Y; Gao, Y; Hu, Z; Jiang, J; Li, L; Li, W; Mang, Y; Ran, J; Yang, C; Zhang, S; Zhao, Y; Zhu, J, 2023) |
| "Statins, metformin, and aspirin have been reported to reduce the incidence of hepatocellular carcinoma (HCC)." | 8.31 | Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis. ( Aminizadeh, E; Büchler, MW; Chang, DH; Golriz, M; Khajeh, E; Klotz, R; Longerich, T; Mehrabi, A; Merle, U; Moghadam, AD; Ramouz, A; Springfeld, C, 2023) |
| "This study examined whether metformin can enhance the radiation response in a hepatocellular carcinoma (HCC) xenograft mice model and patient population." | 8.12 | Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study. ( Jang, WI; Jeong, JH; Kim, JS; Kim, MS; Kim, W, 2022) |
| "Metformin (MET) can effectively treat endometrial hyperplasia (EH), and the expression of glucose transporter type 4 insulin‑responsive (GLUT4) is closely associated with the development of EH." | 8.12 | Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling. ( Chen, L; Li, R; Liu, J; Ning, Y; Zhao, Y; Zhu, X, 2022) |
| "The study aims to investigate the effect of metformin on Hepatocellular carcinoma (HCC) patients with type 2 diabetes mellitus (T2DM) who received transarterial chemoembolization (TACE) for the first time." | 8.12 | Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes. ( Chen, ML; Han, JJ; Sun, YD; Tian, SL; Wu, CX; Zhang, H; Zhang, JB, 2022) |
| "This study aimed to expand our understanding of metformin (Met) in inhibiting hepatocellular carcinoma (HCC) progression and to investigate its underlying mechanism." | 8.02 | Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. ( Guo, L; He, X; Ji, X; Li, A; Shen, Z; Wu, T; Zhang, D; Zhou, H; Zhu, X, 2021) |
| "Metformin is associated with improved survival among hepatocellular carcinoma (HCC) patients with diabetes mellitus." | 7.96 | Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. ( Lin, Y; Luo, CS; Shi, J; Zhou, WP, 2020) |
| " In this study, we investigated the potential effects of acute systemic hypoxia itself and in combination with metformin on hepatocellular carcinoma (HCC) growth and metastasis in a mouse model of HCC." | 7.96 | Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice. ( Huang, Y; Lin, H; Ren, M; Wang, H; Xu, F; Zhou, W, 2020) |
| "It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 7.96 | Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. ( Chuang, PH; Hsieh, MH; Hsieh, TH; Kao, CC; Kao, JT; Kao, TY; Lai, HC; Peng, CY, 2020) |
| "The effects of epigallocatechin-3-gallate (EGCG) and metformin single treatment have been tested against hepatocellular carcinoma (HCC)." | 7.91 | Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study. ( Abdel-Hameed, ND; Abdelaleem, OO; El Amin Ali, AM; Hassouna, A; Khalifa, WA; Mohammed, RA; Sabry, D, 2019) |
| "We assessed racial/ethnic disparity in hepatocellular carcinoma (HCC) incidence among men with type 2 diabetes (T2D) but without chronic liver diseases (CLD), and whether metformin use modified the disparity." | 7.91 | Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases. ( Kuhn, J; Lam, YF; MacCarthy, D; Ramirez, AG; Schmidt, S; Shah, DP; Tenner, L; Wang, CP, 2019) |
| "We investigated metformin-induced cytotoxic effects in vitro and assessed the chemopreventive effects of metformin in patients undergoing hepatic resection (HR) for hepatocellular carcinoma (HCC)." | 7.88 | Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From ( Ahn, CS; Ha, TY; Hwang, S; Jung, DH; Jwa, E; Kang, WH; Kim, KH; Kim, N; Lee, KJ; Lee, SG; Lee, YJ; Moon, DB; Park, GC; Song, GW; Tak, E, 2018) |
| "Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires confirmation." | 7.88 | Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. ( Tseng, CH, 2018) |
| "In 2015, we published a study on a small series of patients with hepatocellular carcinoma (HCC) treated chronically with metformin for type II diabetes mellitus (DM2) who showed a poorer response to sorafenib." | 7.85 | Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. ( Aprile, G; Brunetti, O; Casadei Gardini, A; Cascinu, S; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Granato, AM; Marisi, G; Negrini, G; Palmieri, V; Passardi, A; Perrone, G; Santini, D; Scartozzi, M; Silvestris, N; Tamburini, E; Tovoli, F; Valgiusti, M; Vespasiani-Gentilucci, U, 2017) |
| "The multi‑kinase inhibitor sorafenib is the only drug for which randomized control trials have shown improved patient survival in advanced hepatocellular carcinoma (HCC)." | 7.85 | Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. ( Fan, N; Feng, T; Hou, Z; Huang, Q; Li, Y; Ling, S; Liu, L; Liu, Y; Shi, L; Song, L; Tian, Y; Wang, M; Xu, F; Yang, X; Zhao, F, 2017) |
| "A 52-year-old man with a 9-year history of hepatic hemangioma was treated with the anti-diabetic drug metformin, resulting in complete remission of the tumor." | 7.85 | A case of liver hemangioma with markedly reduced tumor size after metformin treatment: a case report. ( Okumura, T; Ono, M; Sawada, K, 2017) |
| " In the present study, the effects of metformin on the development and recurrence of hepatocellular carcinoma (HCC) were investigated using the diethylnitrosamine (DEN)‑induced rat model of HCC." | 7.83 | Metformin inhibits early stage diethylnitrosamine‑induced hepatocarcinogenesis in rats. ( Chang, M; Choi, HJ; Jang, JJ; Jang, S; Jo, W; Lee, HJ; Park, HK; Ryu, JE; Son, WC; Yu, ES, 2016) |
| "We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression." | 7.83 | Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016) |
| "Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.83 | Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016) |
| "Accumulated evidences indicate metformin is associated with reduced risk of hepatocellular carcinoma (HCC) in diabetic patients, which inspired researchers to explore its therapeutic potentials in HCC." | 7.81 | Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells. ( Qu, H; Yang, X, 2015) |
| "Previous studies have shown that metformin or statins may decrease hepatocellular carcinoma (HCC) in diabetic patients." | 7.81 | Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia. ( Chen, HH; Kao, CH; Lin, MC; Muo, CH; Sung, FC; Yeh, SY, 2015) |
| "The present study aimed to evaluate the effects of metformin on the clinical outcomes of patients receiving radiotherapy for inoperable hepatocellular carcinoma." | 7.81 | Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis. ( Chang, AR; Han, CJ; Jang, HS; Jang, WI; Kay, CS; Kim, M; Kim, MS; Lee, DS; Lim, JS; Park, HJ; Park, SC; Seo, YS; Yoo, HJ, 2015) |
| " The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells." | 7.80 | Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014) |
| "To assess whether metformin, which has a chemopreventive effect in chronic liver disease, has any chemotherapeutic effect in hepatocellular carcinoma." | 7.80 | Metformin does not improve survival in patients with hepatocellular carcinoma. ( Bhat, M; Chaiteerakij, R; Giama, NH; Gores, GJ; Harmsen, WS; Roberts, LR; Schleck, CD; Therneau, TM; Yang, JD, 2014) |
| "to investigate the effects of antidiabetic drug metformin on proliferation and apoptosis in human hepatocellular carcinoma cell line Huh-7 cells." | 7.79 | [Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism]. ( Lin, F; Wen, T; Wu, GY; Yan, W, 2013) |
| "Type 2 diabetes mellitus is associated with a higher risk of hepatocellular carcinoma (HCC), which is attenuated by the use of metformin." | 7.79 | Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. ( Chang, CC; Chen, HP; Chen, TT; Lin, JH; Lin, JT; Shieh, JJ; Wu, CY; Wu, MS, 2013) |
| "Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols." | 7.78 | Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012) |
| "Metformin is an oral hypoglycemic drug, the first option used to treat type 2 diabetes mellitus due to its high efficacy and low cost." | 7.01 | Recent Insights of Metformin on Hepatocellular Carcinoma (HCC). ( Chen, D; Jiang, S; Wang, K; Zhang, K; Zhang, X, 2023) |
| "Metformin treatment significantly prolongs the OS and decreases the recurrence rate for HCC patients with T2DM after curative HCC therapy." | 6.82 | The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy. ( Hao, J; Ma, J; Wang, J; Yuan, B, 2022) |
| "Metformin treatment has been shown to be effective at alleviating hepatic lipogenesis in animal models of NAFLD, with a variety of mechanisms being deemed responsible." | 6.72 | Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. ( Chattipakorn, N; Leerapun, A; Pinyopornpanish, K, 2021) |
| "The key histologic feature of nonalcoholic steatohepatitis (NASH) is hepatocellular ballooning (HB)." | 6.50 | Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). ( Doycheva, I; Loomba, R, 2014) |
| "Metformin treatment was associated with reduced risk of HCC in diabetic patients." | 6.49 | Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. ( Fang, L; Gao, C; Yao, SK; Zhang, H; Zhao, HC, 2013) |
| "Although there are many options for the treatment of hepatocellular carcinoma, such as surgical resection, interventional therapy, radiotherapy, chemotherapy, targeted therapy and liver transplantation, the poor therapeutic effect seriously reduces the quality of life for patients and also increases the social and economic burden." | 5.72 | Role of metformin in the diagnosis, prevention, and treatment of hepatocellular carcinoma. ( Liu, W; Xiong, S, 2022) |
| "Metformin is a commonly used drug for the treatment of diabetes." | 5.72 | Metformin inhibits the development and metastasis of colorectal cancer. ( Hasegawa, H; Ishida, T; Kitagawa, Y; Okabayashi, K; Seishima, R; Shigeta, K; Sugiura, K; Tsuruta, M, 2022) |
| "Metformin use was associated with significantly higher objective response rate (ORR) in the overall and PS-matched cohort (79." | 5.72 | Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. ( Choi, GH; Choi, WJ; Choi, WS; Jang, ES; Jang, S; Jeong, SH; Jung, WJ; Kim, JW; Lee, JH; Park, J; Yoon, CJ, 2022) |
| ", concomitant versus sequential dosing regimens." | 5.62 | Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells. ( Bardin, C; Blanchet, B; Desbois-Mouthon, C; Hamoudi, RA; Harati, R; Praz, F; Vandamme, M, 2021) |
| "Metformin treatment decreased ATXN7L3B-induced tumor-initiating ability in a HCC mouse model, implying that metformin may inhibit cancer stemness by downregulating ATXN7L3B." | 5.62 | ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin. ( Cao, N; Cha, JH; Chen, B; Yan, M; Yan, X; Yang, WH; Ye, P, 2021) |
| "This phase I dose de-escalation study aimed to assess the tolerability, safety, pharmacokinetics (PK), and efficacy of sequentially decreasing doses of sorafenib in combination (SAM) with atorvastatin (A, 10 mg) and metformin (M, 500 mg BD) in patients with advanced hepatocellular carcinoma (HCC)." | 5.51 | Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). ( Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S, 2022) |
| "Metformin has a synergistic benefit with radiotherapy in some cancers, but remains unclear in HCC." | 5.51 | Metformin enhances radiosensitivity in hepatocellular carcinoma by inhibition of specificity protein 1 and epithelial-to-mesenchymal transition. ( Guo, J; Huang, TR; Huang, YY; Wang, J; Zhang, KF, 2019) |
| "Treatment with metformin altered macrophage polarization, reduced liver size and reduced micronuclei formation in NAFLD/NASH-associated HCC larvae." | 5.51 | Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. ( de Oliveira, S; Golenberg, N; Graves, AL; Houseright, RA; Huttenlocher, A; Korte, BG; Miskolci, V, 2019) |
| "Co-treatment of metformin and sorafenib was associated with a survival disadvantage." | 5.51 | Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. ( Hinrichs, JB; Ivanyi, P; Kirstein, MM; Koch, S; Manns, MP; Marhenke, S; Pinter, M; Rodt, T; Scheiner, B; Schulte, L; Schweitzer, N; Vogel, A; Voigtländer, T; Weinmann, A, 2019) |
| "The incidence of hepatocellular carcinoma deriving from metabolic dysfunctions has increased in the last years." | 5.51 | Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. ( Bandini, E; Casadei-Gardini, A; Cascinu, S; Cravero, P; Cucchetti, A; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Ghetti, M; Gramantieri, L; Granato, AM; La Barba, G; Marisi, G; Santini, D; Scarpi, E; Scartozzi, M; Vespasiani-Gentilucci, U, 2019) |
| "High mortality rates in ovarian and liver cancer are largely a result of resistance to currently used chemotherapy." | 5.48 | Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. ( Bukowska, B; Marczak, A; Rogalska, A, 2018) |
| "Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells." | 5.48 | Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). ( Guo, X; Yang, L; Yang, Q, 2018) |
| "All patients registered as having hepatocellular carcinoma between January 1995 and December 2011 in a nationwide database were retrospectively analysed." | 5.46 | Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection. ( Chan, KM; Chiou, MJ; Chou, HS; Hsu, JT; Kuo, CF; Lee, CF; Lee, WC; Wang, YC; Wu, TH; Wu, TJ, 2017) |
| "Metformin is an attractive agent for chemoprevention because it is inexpensive, has a favorable safety profile, and is well tolerated over long time periods." | 5.43 | Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. ( Chung, RT; DePeralta, DK; Fuchs, BC; Ghoshal, S; Lanuti, M; Lauwers, GY; Schmidt, B; Tanabe, KK; Wei, L, 2016) |
| "Metformin plays an anti-proliferative role in tumor cells in many types of cancer." | 5.43 | Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016) |
| "Arsenic trioxide (ATO) is a traditional Asian medicine, and a phase II study has shown that treatment with ATO alone was not effective against HCC." | 5.42 | Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression. ( Ling, S; Sun, D; Tian, Y; Wang, L; Yang, X, 2015) |
| "Emerging data suggest that statins, aspirin and metformin may protect against hepatocellular carcinoma (HCC) development." | 5.41 | Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. ( Chan, KE; Chee, D; Fu, CE; Goh, XL; Huang, DQ; Kim, BK; Lee, SW; Lim, WH; Loomba, R; Muthiah, MD; Ng, CH; Nguyen, MH; Syn, N; Tamaki, N; Tan, C; Tan, DJH; Tan, EX; Xiao, J; Yong, JN; Zeng, RW, 2023) |
| "Metformin is a commonly used oral anti-hyperglycemic agent of the biguanide family." | 5.40 | Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. ( Deguchi, A; Fujita, K; Himoto, T; Iwama, H; Kato, K; Kobara, H; Kobayashi, M; Kurokohchi, K; Maeda, E; Masaki, T; Mimura, S; Miyoshi, H; Mori, H; Morishita, A; Murao, K; Nomura, T; Okano, K; Sakamoto, T; Suzuki, Y; Tani, J; Toyota, Y; Yoneyama, H, 2014) |
| "Metformin was also found to significantly inhibit the expression and secretion of MMP-9 and uPA in HCC cells, and suppress the phosphorylation of ERK1/2 and JNK1/2." | 5.40 | Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. ( Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF, 2014) |
| "Metformin has been widely used as an oral drug for diabetes mellitus for approximately 60 years." | 5.39 | Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. ( Chiba, T; Iwama, A; Kanai, F; Koide, S; Motoyama, T; Ogasawara, S; Ooka, Y; Oshima, M; Saito, T; Suzuki, E; Tada, M; Takiguchi, Y; Tawada, A; Yokosuka, O; Yuki, K; Zen, Y, 2013) |
| "Metformin treatment also upregulated the expression of phosphorylated AMPK protein in xenograft tissues." | 5.39 | Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. ( Cai, B; Cai, X; Chen, X; Cheng, J; Hu, H; Hu, X; Huang, J; Jing, X; Li, Y; Tan, X; Wang, Q, 2013) |
| "Here we report effects of metformin on hepatocellular carcinoma (HCC) Hep-G2 cells and details of molecular mechanisms of metformin activity." | 5.38 | Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. ( Lu, QJ; Wu, GY; Xiong, Y; Zhao, J, 2012) |
| "In 84% of the cases, type 2 diabetes mellitus has been present before the HCC diagnosis." | 5.36 | Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. ( Balbi, M; Casarin, P; Donadon, V; Mas, MD; Zanette, G, 2010) |
| "The views regarding the associations between metformin use and hepatocellular carcinoma (HCC) among diabetes mellitus (DM) patients are divisive." | 5.22 | Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. ( Li, Q; Sui, C; Xu, H; Zhang, H, 2022) |
| "Several studies have reported that metformin can reduce the risk of hepatocellular carcinoma (HCC) in diabetes patients." | 4.91 | Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. ( Bramer, WM; Hernanda, PY; Li, J; Pan, Q; Peppelenbosch, MP; van Luijk, J, 2015) |
| "To evaluate the safety and efficacy of metformin in patients with type 2 diabetes mellitus (T2DM) and chronic hepatitis C virus (HCV) with or without cirrhosis and hepatocellular carcinoma (HCC)." | 4.89 | Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. ( Harris, K; Smith, L, 2013) |
| "The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study." | 4.31 | Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023) |
| "To investigate the impact of metformin on survival of diabetic patients following surgery for colorectal cancer (CRC)." | 4.31 | The impact of metformin on survival in diabetes patients with operable colorectal cancer: A nationwide retrospective cohort study. ( Chu, PT; Chuang, TJ; Huang, SH; Huang, WC; Wang, JH; Wu, TH, 2023) |
| "Lenvatinib is a first-line drug commonly used in the treatment of advanced hepatocellular carcinoma (HCC)." | 4.31 | Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway. ( Cen, X; Cheng, Y; Lu, J; Lu, Y; Luo, C; Wang, F; Xie, C; Yin, Z; Zhan, P, 2023) |
| "Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3, and it inhibits HCC progression." | 4.31 | Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3. ( Dong, Y; Gao, Y; Hu, Z; Jiang, J; Li, L; Li, W; Mang, Y; Ran, J; Yang, C; Zhang, S; Zhao, Y; Zhu, J, 2023) |
| "Statins, metformin, and aspirin have been reported to reduce the incidence of hepatocellular carcinoma (HCC)." | 4.31 | Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis. ( Aminizadeh, E; Büchler, MW; Chang, DH; Golriz, M; Khajeh, E; Klotz, R; Longerich, T; Mehrabi, A; Merle, U; Moghadam, AD; Ramouz, A; Springfeld, C, 2023) |
| "Metformin, a traditional first-line pharmacological treatment for type 2 diabetes, has recently been shown to have anti-cancer effects on hepatocellular carcinoma (HCC)." | 4.12 | Metformin exerts anti-tumor effects via Sonic hedgehog signaling pathway by targeting AMPK in HepG2 cells. ( Chen, B; Hu, A; Hu, Z; Huang, L; Ji, W; Lai, Z; Liu, Y; Ye, J; Zhang, M; Zhong, J; Zou, H, 2022) |
| "This study examined whether metformin can enhance the radiation response in a hepatocellular carcinoma (HCC) xenograft mice model and patient population." | 4.12 | Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study. ( Jang, WI; Jeong, JH; Kim, JS; Kim, MS; Kim, W, 2022) |
| "Metformin (MET) can effectively treat endometrial hyperplasia (EH), and the expression of glucose transporter type 4 insulin‑responsive (GLUT4) is closely associated with the development of EH." | 4.12 | Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling. ( Chen, L; Li, R; Liu, J; Ning, Y; Zhao, Y; Zhu, X, 2022) |
| "The study aims to investigate the effect of metformin on Hepatocellular carcinoma (HCC) patients with type 2 diabetes mellitus (T2DM) who received transarterial chemoembolization (TACE) for the first time." | 4.12 | Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes. ( Chen, ML; Han, JJ; Sun, YD; Tian, SL; Wu, CX; Zhang, H; Zhang, JB, 2022) |
| "This study aimed to expand our understanding of metformin (Met) in inhibiting hepatocellular carcinoma (HCC) progression and to investigate its underlying mechanism." | 4.02 | Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. ( Guo, L; He, X; Ji, X; Li, A; Shen, Z; Wu, T; Zhang, D; Zhou, H; Zhu, X, 2021) |
| "Metformin use in patients with cirrhosis and diabetes appears safe and is associated independently with reduced overall, but not liver-related, mortality, hepatocellular carcinoma, or decompensation after adjusting for concomitant statin and angiotensinogen-converting enzyme inhibitor/angiotensin-2-receptor blocker exposure." | 4.02 | Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. ( Albrecht, J; Aytaman, A; Baytarian, M; Fox, R; Hunt, K; John, BV; Kaplan, DE; Lerer, R; Mehta, R; Serper, M; Taddei, TH; Tessiatore, KM, 2021) |
| "Metformin is associated with improved survival among hepatocellular carcinoma (HCC) patients with diabetes mellitus." | 3.96 | Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. ( Lin, Y; Luo, CS; Shi, J; Zhou, WP, 2020) |
| " In this study, we investigated the potential effects of acute systemic hypoxia itself and in combination with metformin on hepatocellular carcinoma (HCC) growth and metastasis in a mouse model of HCC." | 3.96 | Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice. ( Huang, Y; Lin, H; Ren, M; Wang, H; Xu, F; Zhou, W, 2020) |
| "Metformin is an ideal candidate to treat the liver tumor with insulin resistance because of its good performance in the treatment of type 2 diabetes and the advantage in cancer therapy." | 3.96 | Novel Albumin Nanoparticle Enhanced the Anti-Insulin-Resistant-Hepatoma Activity of Metformin. ( Li, JQ; Lin, YR; Lu, Z; Qi, L; Sun, L; Wang, GC; Yu, JM; Zhang, L, 2020) |
| "It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 3.96 | Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. ( Chuang, PH; Hsieh, MH; Hsieh, TH; Kao, CC; Kao, JT; Kao, TY; Lai, HC; Peng, CY, 2020) |
| "The effects of epigallocatechin-3-gallate (EGCG) and metformin single treatment have been tested against hepatocellular carcinoma (HCC)." | 3.91 | Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study. ( Abdel-Hameed, ND; Abdelaleem, OO; El Amin Ali, AM; Hassouna, A; Khalifa, WA; Mohammed, RA; Sabry, D, 2019) |
| "We assessed racial/ethnic disparity in hepatocellular carcinoma (HCC) incidence among men with type 2 diabetes (T2D) but without chronic liver diseases (CLD), and whether metformin use modified the disparity." | 3.91 | Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases. ( Kuhn, J; Lam, YF; MacCarthy, D; Ramirez, AG; Schmidt, S; Shah, DP; Tenner, L; Wang, CP, 2019) |
| "Metformin may protect against hepatocellular carcinoma and mortality among patients with type 2 diabetes." | 3.91 | Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. ( Chalasani, N; Cummings, OW; Desai, AP; Gawrieh, S; Ghabril, M; Saxena, R; Vilar-Gomez, E; Vuppalanchi, R, 2019) |
| "Hepatitis C virus (HCV) infection has been related to increased risk of development of hepatocellular carcinoma (HCC) while metformin (M) and statins treatment seemed to protect against HCC development." | 3.88 | Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. ( Ampuero, J; Del Campo, JA; Gallego, P; Gallego-Durán, R; García-Valdecasas, M; Gil-Gómez, A; Grande, L; Muntané, J; Padillo, FJ; Pastor, H; Rojas, Á; Romero-Gómez, M, 2018) |
| "We investigated metformin-induced cytotoxic effects in vitro and assessed the chemopreventive effects of metformin in patients undergoing hepatic resection (HR) for hepatocellular carcinoma (HCC)." | 3.88 | Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From ( Ahn, CS; Ha, TY; Hwang, S; Jung, DH; Jwa, E; Kang, WH; Kim, KH; Kim, N; Lee, KJ; Lee, SG; Lee, YJ; Moon, DB; Park, GC; Song, GW; Tak, E, 2018) |
| "Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires confirmation." | 3.88 | Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. ( Tseng, CH, 2018) |
| "In 2015, we published a study on a small series of patients with hepatocellular carcinoma (HCC) treated chronically with metformin for type II diabetes mellitus (DM2) who showed a poorer response to sorafenib." | 3.85 | Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. ( Aprile, G; Brunetti, O; Casadei Gardini, A; Cascinu, S; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Granato, AM; Marisi, G; Negrini, G; Palmieri, V; Passardi, A; Perrone, G; Santini, D; Scartozzi, M; Silvestris, N; Tamburini, E; Tovoli, F; Valgiusti, M; Vespasiani-Gentilucci, U, 2017) |
| "The multi‑kinase inhibitor sorafenib is the only drug for which randomized control trials have shown improved patient survival in advanced hepatocellular carcinoma (HCC)." | 3.85 | Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. ( Fan, N; Feng, T; Hou, Z; Huang, Q; Li, Y; Ling, S; Liu, L; Liu, Y; Shi, L; Song, L; Tian, Y; Wang, M; Xu, F; Yang, X; Zhao, F, 2017) |
| "A 52-year-old man with a 9-year history of hepatic hemangioma was treated with the anti-diabetic drug metformin, resulting in complete remission of the tumor." | 3.85 | A case of liver hemangioma with markedly reduced tumor size after metformin treatment: a case report. ( Okumura, T; Ono, M; Sawada, K, 2017) |
| " In the present study, the effects of metformin on the development and recurrence of hepatocellular carcinoma (HCC) were investigated using the diethylnitrosamine (DEN)‑induced rat model of HCC." | 3.83 | Metformin inhibits early stage diethylnitrosamine‑induced hepatocarcinogenesis in rats. ( Chang, M; Choi, HJ; Jang, JJ; Jang, S; Jo, W; Lee, HJ; Park, HK; Ryu, JE; Son, WC; Yu, ES, 2016) |
| "We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression." | 3.83 | Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016) |
| "Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.83 | Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016) |
| "The purpose of this study was to investigate the effect of metformin on the responses of hepatocellular carcinoma (HCC) cells to γ-rays (low-linear energy transfer (LET) radiation) and carbon-ion beams (high-LET radiation)." | 3.83 | Metformin enhances the radiosensitivity of human liver cancer cells to γ-rays and carbon ion beams. ( Furusawa, Y; Han, S; Jung, WG; Kim, EH; Kim, MS; Sai, S; Uzawa, A, 2016) |
| "Accumulated evidences indicate metformin is associated with reduced risk of hepatocellular carcinoma (HCC) in diabetic patients, which inspired researchers to explore its therapeutic potentials in HCC." | 3.81 | Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells. ( Qu, H; Yang, X, 2015) |
| " Metformin, which is widely used in the treatment of diabetes, ameliorates insulin sensitivity." | 3.81 | Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice. ( Baba, A; Kochi, T; Kubota, M; Moriwaki, H; Ohno, T; Shimizu, M; Shirakami, Y; Tanaka, T; Tsurumi, H, 2015) |
| "Previous studies have shown that metformin or statins may decrease hepatocellular carcinoma (HCC) in diabetic patients." | 3.81 | Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia. ( Chen, HH; Kao, CH; Lin, MC; Muo, CH; Sung, FC; Yeh, SY, 2015) |
| "The present study aimed to evaluate the effects of metformin on the clinical outcomes of patients receiving radiotherapy for inoperable hepatocellular carcinoma." | 3.81 | Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis. ( Chang, AR; Han, CJ; Jang, HS; Jang, WI; Kay, CS; Kim, M; Kim, MS; Lee, DS; Lim, JS; Park, HJ; Park, SC; Seo, YS; Yoo, HJ, 2015) |
| "The purpose of this study was to investigate the efficacy of metformin as a radiosensitizer for use in combination therapy for human hepatocellular carcinoma (HCC)." | 3.80 | Low and high linear energy transfer radiation sensitization of HCC cells by metformin. ( Cho, CK; Jeong, JH; Jeong, YK; Jung, WG; Kim, EH; Kim, MS, 2014) |
| " The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells." | 3.80 | Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014) |
| "To assess whether metformin, which has a chemopreventive effect in chronic liver disease, has any chemotherapeutic effect in hepatocellular carcinoma." | 3.80 | Metformin does not improve survival in patients with hepatocellular carcinoma. ( Bhat, M; Chaiteerakij, R; Giama, NH; Gores, GJ; Harmsen, WS; Roberts, LR; Schleck, CD; Therneau, TM; Yang, JD, 2014) |
| " Metformin, a first-line drug for diabetes mellitus type 2, appears to be associated with a lower risk and improved outcomes in hepatocellular carcinoma (HCC)." | 3.79 | Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. ( He, L; He, Z; Hong, J; Jia, X; Liu, J; Xian, L; Yi, G; Yuan, T; Zhou, X, 2013) |
| "to investigate the effects of antidiabetic drug metformin on proliferation and apoptosis in human hepatocellular carcinoma cell line Huh-7 cells." | 3.79 | [Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism]. ( Lin, F; Wen, T; Wu, GY; Yan, W, 2013) |
| "Type 2 diabetes mellitus is associated with a higher risk of hepatocellular carcinoma (HCC), which is attenuated by the use of metformin." | 3.79 | Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. ( Chang, CC; Chen, HP; Chen, TT; Lin, JH; Lin, JT; Shieh, JJ; Wu, CY; Wu, MS, 2013) |
| "Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols." | 3.78 | Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012) |
| "A total of 100 consecutive diabetic patients (53 men, age 61 ± 11 yr) with ongoing HCV cirrhosis and no contraindication for metformin were included in a screening program for hepatocellular carcinoma (HCC)." | 3.77 | Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. ( Aout, M; Beaugrand, M; Bourcier, V; Charif, I; Cosson, E; Ganne-Carrie, N; Grando-Lemaire, V; Mahmoudi, A; Nkontchou, G; Trinchet, JC; Vicaut, E, 2011) |
| "Metformin is an oral hypoglycemic drug, the first option used to treat type 2 diabetes mellitus due to its high efficacy and low cost." | 3.01 | Recent Insights of Metformin on Hepatocellular Carcinoma (HCC). ( Chen, D; Jiang, S; Wang, K; Zhang, K; Zhang, X, 2023) |
| "Thirty patients with type 2 diabetes were randomized to weekly EXE and daily DAPA (n = 16) or weekly PLAC and daily DAPA (n = 14)." | 3.01 | Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-contr ( Bastian, M; Brath, H; Harreiter, J; Just, I; Kautzky-Willer, A; Klepochova, R; Krššák, M; Leutner, M; Schelkshorn, C, 2021) |
| "Metformin treatment significantly prolongs the OS and decreases the recurrence rate for HCC patients with T2DM after curative HCC therapy." | 2.82 | The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy. ( Hao, J; Ma, J; Wang, J; Yuan, B, 2022) |
| "Fetuin A levels were elevated in NAFLD." | 2.77 | Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. ( Aasheim, ET; Aukrust, P; Birkeland, KI; Dahl, TB; Gladhaug, IP; Haaland, T; Halvorsen, B; Haukeland, JW; Johansen, OE; Konopski, Z; Løberg, EM; Wium, C; Yndestad, A, 2012) |
| "Metformin treatment has been shown to be effective at alleviating hepatic lipogenesis in animal models of NAFLD, with a variety of mechanisms being deemed responsible." | 2.72 | Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. ( Chattipakorn, N; Leerapun, A; Pinyopornpanish, K, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is strongly linked to the global epidemic of obesity and type 2 diabetes mellitus (T2DM)." | 2.72 | Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC. ( Wang, H; Xiao, H; Zhang, Y, 2021) |
| "Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| "Metformin has garnered more interest as a chemo-preventive agent given the increased liver cancer risk in diabetic patients." | 2.55 | Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. ( Ma, S; Tan, H; Xiao, Y; Zheng, Y; Zhou, P, 2017) |
| "Metformin has garnered considerable interest as a chemo-preventive and chemo-therapeutic agent given the increased risk of liver cancer among diabetic patients." | 2.53 | Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. ( Ma, SJ; Tan, HZ; Xiao, YN; Zheng, YX; Zhou, PC, 2016) |
| "Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC)." | 2.52 | Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. ( Noureddin, M; Rinella, ME, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and comprises a liver disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) with risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC)." | 2.52 | Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. ( Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Munda, P; Rechling, C; Trauner, M; Traussnigg, S, 2015) |
| "The key histologic feature of nonalcoholic steatohepatitis (NASH) is hepatocellular ballooning (HB)." | 2.50 | Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). ( Doycheva, I; Loomba, R, 2014) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| "Metformin treatment was associated with reduced risk of HCC in diabetic patients." | 2.49 | Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. ( Fang, L; Gao, C; Yao, SK; Zhang, H; Zhao, HC, 2013) |
| "Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, comprises a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis." | 2.49 | Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. ( Baldelli, E; Carulli, L; George, J; Hebbard, L; Loria, P; Maurantonio, M, 2013) |
| "Metformin treatment was potentially protective." | 2.48 | Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. ( Cao, W; Kang, D; Liu, Z; Wang, P; Wang, Y, 2012) |
| "In patients with NAFLD, those with type 2 diabetes mellitus (DM) have a high risk of progression to HCC." | 1.72 | Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. ( Dai, J; El-Serag, HB; Kanwal, F; Kramer, JR; Li, L; Natarajan, Y; Yu, X, 2022) |
| "Metformin treatment is associated with improved OS after HCC diagnosis." | 1.72 | The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival. ( Berhane, S; Cuthbertson, DJ; Dhanaraj, S; Graef, S; Hydes, TJ; Johnson, PJ; Singh, P; Skowronska, A; Tahrani, A; Teng, M, 2022) |
| "It thus remains unclear which hepatocellular carcinoma (HCC) patient subpopulation(s) can benefit from metformin treatment." | 1.72 | Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer. ( Cai, P; Cai, Y; Deng, J; Feng, J; Gao, P; Jia, W; Lu, H; Lu, Z; Ma, W; Qu, K; Shu, Y; Sun, Y; Tian, W; Yang, H; Zhang, H; Zhou, Z, 2022) |
| "Although there are many options for the treatment of hepatocellular carcinoma, such as surgical resection, interventional therapy, radiotherapy, chemotherapy, targeted therapy and liver transplantation, the poor therapeutic effect seriously reduces the quality of life for patients and also increases the social and economic burden." | 1.72 | Role of metformin in the diagnosis, prevention, and treatment of hepatocellular carcinoma. ( Liu, W; Xiong, S, 2022) |
| "Metformin is a commonly used drug for the treatment of diabetes." | 1.72 | Metformin inhibits the development and metastasis of colorectal cancer. ( Hasegawa, H; Ishida, T; Kitagawa, Y; Okabayashi, K; Seishima, R; Shigeta, K; Sugiura, K; Tsuruta, M, 2022) |
| "Metformin use was associated with significantly higher objective response rate (ORR) in the overall and PS-matched cohort (79." | 1.72 | Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. ( Choi, GH; Choi, WJ; Choi, WS; Jang, ES; Jang, S; Jeong, SH; Jung, WJ; Kim, JW; Lee, JH; Park, J; Yoon, CJ, 2022) |
| "Metformin upregulated glycolysis in liver cancer cells, thereby increasing sensitivity to the DCA treatment." | 1.62 | Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1. ( Cho, Y; Choi, DH; Kim, SY; Kim, TS; Lee, CY; Lee, M; Park, M; Shim, MS, 2021) |
| "Metformin use over time was associated with a significant reduction in risk of death or liver transplantation (aHR, 0." | 1.62 | Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. ( Adams, LA; Aller-de la Fuente, R; Calzadilla-Bertot, L; Castellanos, M; Eslam, M; George, J; Romero-Gomez, M; Vilar-Gomez, E; Wong, GL; Wong, VW, 2021) |
| ", concomitant versus sequential dosing regimens." | 1.62 | Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells. ( Bardin, C; Blanchet, B; Desbois-Mouthon, C; Hamoudi, RA; Harati, R; Praz, F; Vandamme, M, 2021) |
| "Metformin treatment decreased ATXN7L3B-induced tumor-initiating ability in a HCC mouse model, implying that metformin may inhibit cancer stemness by downregulating ATXN7L3B." | 1.62 | ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin. ( Cao, N; Cha, JH; Chen, B; Yan, M; Yan, X; Yang, WH; Ye, P, 2021) |
| "Targeting AMPK and lipid metabolism of hepatocellular cancer stem cells is a promising strategy to face stemness and chemotherapy resistance." | 1.56 | Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells. ( Bort, A; de Miguel, I; Diaz-Laviada, I; Mateos-Gómez, PA; Sánchez, BG, 2020) |
| "Metformin has plausible direct and indirect anti-cancer properties against pancreatic adenocarcinoma cells." | 1.56 | An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases. ( Broadhurst, PJ; Hart, AR, 2020) |
| "Metformin is a drug used in the treatment of type 2 diabetes." | 1.56 | Metformin inhibits TGF‑β1‑induced epithelial‑mesenchymal transition and liver metastasis of pancreatic cancer cells. ( Endo, Y; Hirai, Y; Inoue, K; Ishikawa, T; Itoh, Y; Kamada, K; Matsumura, S; Mizushima, K; Naito, Y; Oka, K; Okayama, T; Ota, T; Sakamoto, N; Takagi, T; Uchiyama, K; Yoshida, J, 2020) |
| "Metformin has a synergistic benefit with radiotherapy in some cancers, but remains unclear in HCC." | 1.51 | Metformin enhances radiosensitivity in hepatocellular carcinoma by inhibition of specificity protein 1 and epithelial-to-mesenchymal transition. ( Guo, J; Huang, TR; Huang, YY; Wang, J; Zhang, KF, 2019) |
| "Treatment with metformin altered macrophage polarization, reduced liver size and reduced micronuclei formation in NAFLD/NASH-associated HCC larvae." | 1.51 | Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. ( de Oliveira, S; Golenberg, N; Graves, AL; Houseright, RA; Huttenlocher, A; Korte, BG; Miskolci, V, 2019) |
| "Co-treatment of metformin and sorafenib was associated with a survival disadvantage." | 1.51 | Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. ( Hinrichs, JB; Ivanyi, P; Kirstein, MM; Koch, S; Manns, MP; Marhenke, S; Pinter, M; Rodt, T; Scheiner, B; Schulte, L; Schweitzer, N; Vogel, A; Voigtländer, T; Weinmann, A, 2019) |
| "HepaRG is a proliferative human hepatoma-derived cell line that can be differentiated into hepatocyte-like and biliary-like cells." | 1.51 | Comparison of HepaRG cells following growth in proliferative and differentiated culture conditions reveals distinct bioenergetic profiles. ( Young, CKJ; Young, MJ, 2019) |
| "The incidence of hepatocellular carcinoma deriving from metabolic dysfunctions has increased in the last years." | 1.51 | Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. ( Bandini, E; Casadei-Gardini, A; Cascinu, S; Cravero, P; Cucchetti, A; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Ghetti, M; Gramantieri, L; Granato, AM; La Barba, G; Marisi, G; Santini, D; Scarpi, E; Scartozzi, M; Vespasiani-Gentilucci, U, 2019) |
| "High mortality rates in ovarian and liver cancer are largely a result of resistance to currently used chemotherapy." | 1.48 | Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. ( Bukowska, B; Marczak, A; Rogalska, A, 2018) |
| "Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells." | 1.48 | Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). ( Guo, X; Yang, L; Yang, Q, 2018) |
| "Metformin was inversely associated with liver cancer (adjusted hazard ratio [aHR] = 0." | 1.48 | Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. ( Greevy, RA; Griffin, MR; Grijalva, CG; Hackstadt, AJ; Hung, AM; McGowan, LED; Murff, HJ; Roumie, CL, 2018) |
| "All patients registered as having hepatocellular carcinoma between January 1995 and December 2011 in a nationwide database were retrospectively analysed." | 1.46 | Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection. ( Chan, KM; Chiou, MJ; Chou, HS; Hsu, JT; Kuo, CF; Lee, CF; Lee, WC; Wang, YC; Wu, TH; Wu, TJ, 2017) |
| "Hepatocellular carcinoma is the most common primary liver malignancy, commonly a sequelae of hepatitis C infection, but can complicate cirrhosis of any cause." | 1.46 | Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. ( Kasmari, AJ; Leslie, D; Liu, G; McGarrity, T; Riley, T; Welch, A, 2017) |
| "A total of 109 patients who had chronic hepatitis B and were receiving NA therapy were analyzed." | 1.43 | Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. ( Arai, K; Honda, M; Kaneko, S; Kawaguchi, K; Mizukoshi, E; Nakamura, M; Oishi, N; Okada, H; Sakai, Y; Shimakami, T; Shirasaki, T; Terashima, T; Wang, X; Yamashita, T, 2016) |
| "Metformin is an attractive agent for chemoprevention because it is inexpensive, has a favorable safety profile, and is well tolerated over long time periods." | 1.43 | Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. ( Chung, RT; DePeralta, DK; Fuchs, BC; Ghoshal, S; Lanuti, M; Lauwers, GY; Schmidt, B; Tanabe, KK; Wei, L, 2016) |
| "In human hepatocellular carcinoma (HCC), upregulation of NANOG is associated with metastasis and a low survival rate, while its downregulation results in a lower colony formation rate and enhanced chemosensitivity." | 1.43 | Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK. ( Ka, SO; Kim, JH; Kim, SJ; Park, BH; Park, JH; Shen, C, 2016) |
| "Metformin plays an anti-proliferative role in tumor cells in many types of cancer." | 1.43 | Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016) |
| "Arsenic trioxide (ATO) is a traditional Asian medicine, and a phase II study has shown that treatment with ATO alone was not effective against HCC." | 1.42 | Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression. ( Ling, S; Sun, D; Tian, Y; Wang, L; Yang, X, 2015) |
| "Recurrent type I endometrial cancer (EC) has poor prognosis and demands novel therapeutic approaches." | 1.42 | Metformin: a modulator of bevacizumab activity in cancer? A case report. ( Aliberti, C; Casarin, A; Indraccolo, S; Nardin, M; Nicoletto, MO; Pomerri, F; Randon, G; Zulato, E, 2015) |
| "The occurrence of HCC or a nonliver cancer was evaluated in patients who either were or were not taking statin or metformin." | 1.42 | Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. ( Chang, CJ; Chen, CI; Fang, YA; Hwang, J; Kuan, CF; Liu, JC; Liu, SH; Miser, JS; Wu, LL; Wu, SY; Yang, HC, 2015) |
| "Co-treatment with metformin or AICAR decreased the TNF-α-induced intracellular TG, accompanied by significantly enhanced AMPK and ACC phosphorylation, suppressed mTOR and p70S6K phosphorylation, and reduced SREBP-1 and FAS expressions." | 1.42 | AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells. ( Gao, R; Goswami, R; Li, Q; Liu, L; Lv, Q; Yang, S; Zhen, Q; Zhou, H, 2015) |
| "Although liver cancer is one of the most responsive types of cancer for reduction of incidence by metformin, the molecular mechanism of the suppression of mTOR in liver remains unknown." | 1.42 | DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. ( Abudukadier, A; Fujita, Y; Fukushima, T; Harashima, S; Hosokawa, M; Inagaki, N; Obara, A; Ogura, M; Oguri, Y, 2015) |
| "Metformin (MET) was successfully loaded on HA capped AuNPs (H-AuNPs) and this formulation binds easily on the surface of the liver cancer cells." | 1.42 | Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). ( Gover Antoniraj, M; Kumar, CS; Raja, MD; Ruckmani, K; Sundar, DS, 2015) |
| "Human hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide particularly in Asia." | 1.42 | Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs. ( Chi, CW; Hsia, CY; Hsu, CC; Lee, HC; Wu, LC; Yeh, TS; Yin, PH, 2015) |
| "Metformin is a commonly used oral anti-hyperglycemic agent of the biguanide family." | 1.40 | Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. ( Deguchi, A; Fujita, K; Himoto, T; Iwama, H; Kato, K; Kobara, H; Kobayashi, M; Kurokohchi, K; Maeda, E; Masaki, T; Mimura, S; Miyoshi, H; Mori, H; Morishita, A; Murao, K; Nomura, T; Okano, K; Sakamoto, T; Suzuki, Y; Tani, J; Toyota, Y; Yoneyama, H, 2014) |
| "Type II diabetes increases liver cancer risk but the risk may be mitigated by anti-diabetic medications." | 1.40 | Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. ( Hagberg, KW; Jick, S; McGlynn, KA; Sahasrabuddhe, VV, 2014) |
| "Metformin was also found to significantly inhibit the expression and secretion of MMP-9 and uPA in HCC cells, and suppress the phosphorylation of ERK1/2 and JNK1/2." | 1.40 | Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. ( Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF, 2014) |
| "Metformin has been widely used as an oral drug for diabetes mellitus for approximately 60 years." | 1.39 | Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. ( Chiba, T; Iwama, A; Kanai, F; Koide, S; Motoyama, T; Ogasawara, S; Ooka, Y; Oshima, M; Saito, T; Suzuki, E; Tada, M; Takiguchi, Y; Tawada, A; Yokosuka, O; Yuki, K; Zen, Y, 2013) |
| "Metformin has recently drawn attention because of its potential antitumor effect." | 1.39 | Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. ( Aoki, K; Atsumi, T; Inoue, H; Ito, Y; Kaji, M; Nagashima, Y; Nakamura, A; Orime, K; Sakamoto, E; Sato, K; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y, 2013) |
| "Metformin treatment also upregulated the expression of phosphorylated AMPK protein in xenograft tissues." | 1.39 | Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. ( Cai, B; Cai, X; Chen, X; Cheng, J; Hu, H; Hu, X; Huang, J; Jing, X; Li, Y; Tan, X; Wang, Q, 2013) |
| " The cytotoxic effect of metformin combined with IR was subsequently determined by clonogenic survival and cell cycle assays, assessment of mitochondrial complex I and lactate dehydrogenase (LDH) activity, measurement of cellular adenosine triphosphate (ATP) levels, comet assay and analyses of the formation and disappearance of phosphorylated histone H2AX (γ-H2AX) protein." | 1.38 | Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. ( Chen, J; He, Z; Hou, M; Jia, X; Liu, J; Shao, X; Yi, G; Yuan, T; Zhang, S, 2012) |
| "Here we report effects of metformin on hepatocellular carcinoma (HCC) Hep-G2 cells and details of molecular mechanisms of metformin activity." | 1.38 | Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. ( Lu, QJ; Wu, GY; Xiong, Y; Zhao, J, 2012) |
| "In a rat hepatoma cell line, inhibition of ATM with KU-55933 attenuated the phosphorylation and activation of AMP-activated protein kinase in response to metformin." | 1.37 | Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. ( Bellenguez, C; Bennett, AJ; Blackwell, JM; Bramon, E; Brown, MA; Burch, L; Carr, F; Casas, JP; Coleman, RL; Colhoun, H; Corvin, A; Craddock, N; Deloukas, P; Doney, AS; Donnelly, LA; Donnelly, P; Dronov, S; Duncanson, A; Edkins, S; Freeman, C; Gray, E; Groves, CJ; Hardie, DG; Harries, LW; Hattersley, AT; Hawley, SA; Holman, RR; Hunt, S; Jankowski, J; Langford, C; Markus, HS; Mathew, CG; McCarthy, MI; Morris, AD; Palmer, CN; Pearson, ER; Peltonen, L; Plomin, R; Rautanen, A; Samani, NJ; Sawcer, SJ; Schofield, C; Spencer, CC; Strange, A; Sutherland, C; Tavendale, R; Trembath, R; Viswanathan, AC; Wood, NW; Zhou, K, 2011) |
| " The covariates included age, gender, other oral anti-hyperglycemic medication, Charlson comorbidity index (CCI) score and metformin exposure dosage and duration." | 1.37 | Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. ( Chang, YH; Hsu, CC; Huang, YC; Lee, MS; Tsai, HN; Wahlqvist, ML, 2011) |
| "In 84% of the cases, type 2 diabetes mellitus has been present before the HCC diagnosis." | 1.36 | Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. ( Balbi, M; Casarin, P; Donadon, V; Mas, MD; Zanette, G, 2010) |
| "Metformin is an antidiabetic drug commonly used to treat type 2 diabetes." | 1.35 | Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. ( Cho, WJ; Choi, HS; Ha, J; Jang, WG; Kim, DK; Kim, YD; Lee, CH; Lee, IK; Lee, YS; Nedumaran, B; Park, KG; Park, YY, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.50) | 18.2507 |
| 2000's | 5 (2.51) | 29.6817 |
| 2010's | 125 (62.81) | 24.3611 |
| 2020's | 68 (34.17) | 2.80 |
| Authors | Studies |
|---|---|
| Mamdouh, AM | 1 |
| Khodeer, DM | 1 |
| Tantawy, MA | 1 |
| Moustafa, YM | 1 |
| Shen, Z | 1 |
| Zhou, H | 4 |
| Li, A | 1 |
| Wu, T | 3 |
| Ji, X | 1 |
| Guo, L | 3 |
| Zhu, X | 4 |
| Zhang, D | 3 |
| He, X | 2 |
| Zhang, Z | 4 |
| Su, T | 1 |
| Han, Y | 1 |
| Yang, Z | 1 |
| Wei, J | 1 |
| Jin, L | 2 |
| Fan, H | 2 |
| Kim, TS | 1 |
| Lee, M | 1 |
| Park, M | 1 |
| Kim, SY | 1 |
| Shim, MS | 1 |
| Lee, CY | 1 |
| Choi, DH | 1 |
| Cho, Y | 1 |
| Wang, Y | 10 |
| Lu, H | 3 |
| Sun, L | 3 |
| Chen, X | 5 |
| Wei, H | 2 |
| Suo, C | 1 |
| Feng, J | 5 |
| Yuan, M | 2 |
| Shen, S | 1 |
| Jia, W | 2 |
| Zhang, H | 9 |
| Li, Z | 5 |
| Zhong, X | 1 |
| Gao, P | 2 |
| Zhang, X | 8 |
| Ogihara, T | 1 |
| Zhu, M | 1 |
| Gantumur, D | 1 |
| Li, Y | 17 |
| Mizoi, K | 1 |
| Kamioka, H | 1 |
| Tsushima, Y | 1 |
| Kramer, JR | 1 |
| Natarajan, Y | 1 |
| Dai, J | 1 |
| Yu, X | 1 |
| Li, L | 7 |
| El-Serag, HB | 1 |
| Kanwal, F | 1 |
| Abdelhamid, AM | 1 |
| Saber, S | 2 |
| Youssef, ME | 1 |
| Gaafar, AGA | 1 |
| Eissa, H | 1 |
| Abd-Eldayem, MA | 1 |
| Alqarni, M | 1 |
| Batiha, GE | 1 |
| Obaidullah, AJ | 1 |
| Shahien, MA | 1 |
| El-Ahwany, E | 2 |
| Amin, NA | 1 |
| Etman, MA | 1 |
| Kaddah, MMY | 1 |
| Abd El-Fattah, EE | 2 |
| Hu, A | 1 |
| Hu, Z | 2 |
| Ye, J | 2 |
| Liu, Y | 6 |
| Lai, Z | 1 |
| Zhang, M | 6 |
| Ji, W | 1 |
| Huang, L | 1 |
| Zou, H | 1 |
| Chen, B | 3 |
| Zhong, J | 1 |
| Hydes, TJ | 1 |
| Cuthbertson, DJ | 1 |
| Graef, S | 1 |
| Berhane, S | 1 |
| Teng, M | 1 |
| Skowronska, A | 1 |
| Singh, P | 2 |
| Dhanaraj, S | 1 |
| Tahrani, A | 1 |
| Johnson, PJ | 1 |
| Jang, WI | 3 |
| Kim, MS | 5 |
| Jeong, JH | 2 |
| Kim, W | 1 |
| Kim, JS | 1 |
| Ma, W | 1 |
| Tian, W | 1 |
| Lu, Z | 2 |
| Yang, H | 3 |
| Cai, Y | 2 |
| Cai, P | 1 |
| Sun, Y | 4 |
| Zhou, Z | 1 |
| Deng, J | 1 |
| Shu, Y | 1 |
| Qu, K | 1 |
| Kuburas, R | 1 |
| Gharanei, M | 1 |
| Haussmann, I | 1 |
| Maddock, H | 1 |
| Sandhu, H | 1 |
| Ostwal, V | 1 |
| Ramaswamy, A | 1 |
| Gota, V | 1 |
| Bhargava, PG | 1 |
| Srinivas, S | 1 |
| Shriyan, B | 1 |
| Jadhav, S | 1 |
| Goel, M | 1 |
| Patkar, S | 1 |
| Mandavkar, S | 1 |
| Naughane, D | 1 |
| Daddi, A | 1 |
| Nashikkar, C | 1 |
| Shetty, N | 1 |
| Ankathi, SK | 1 |
| Banavali, SD | 1 |
| Wabitsch, S | 1 |
| McCallen, JD | 1 |
| Kamenyeva, O | 1 |
| Ruf, B | 1 |
| McVey, JC | 1 |
| Kabat, J | 1 |
| Walz, JS | 1 |
| Rotman, Y | 1 |
| Bauer, KC | 1 |
| Craig, AJ | 1 |
| Pouzolles, M | 1 |
| Phadke, I | 1 |
| Catania, V | 1 |
| Green, BL | 1 |
| Fu, C | 1 |
| Diggs, LP | 1 |
| Heinrich, B | 1 |
| Wang, XW | 2 |
| Ma, C | 2 |
| Greten, TF | 1 |
| Xiong, S | 1 |
| Liu, W | 2 |
| Liu, J | 7 |
| Zhao, Y | 4 |
| Chen, L | 8 |
| Li, R | 1 |
| Ning, Y | 1 |
| Zakaria, AY | 1 |
| Lujambio, A | 1 |
| Sarobe, P | 1 |
| Wang, K | 1 |
| Zhang, K | 1 |
| Chen, D | 3 |
| Jiang, S | 1 |
| Sugiura, K | 1 |
| Okabayashi, K | 1 |
| Seishima, R | 1 |
| Ishida, T | 1 |
| Shigeta, K | 1 |
| Tsuruta, M | 1 |
| Hasegawa, H | 1 |
| Kitagawa, Y | 1 |
| Siddharth, S | 1 |
| Kuppusamy, P | 1 |
| Wu, Q | 2 |
| Nagalingam, A | 1 |
| Saxena, NK | 2 |
| Sharma, D | 1 |
| Jung, WJ | 1 |
| Jang, S | 2 |
| Choi, WJ | 1 |
| Park, J | 1 |
| Choi, GH | 1 |
| Jang, ES | 1 |
| Jeong, SH | 2 |
| Choi, WS | 1 |
| Lee, JH | 1 |
| Yoon, CJ | 1 |
| Kim, JW | 1 |
| Chen, ML | 1 |
| Wu, CX | 1 |
| Zhang, JB | 1 |
| Sun, YD | 1 |
| Tian, SL | 1 |
| Han, JJ | 1 |
| Tsai, PC | 1 |
| Kuo, HT | 1 |
| Hung, CH | 1 |
| Tseng, KC | 1 |
| Lai, HC | 2 |
| Peng, CY | 2 |
| Wang, JH | 2 |
| Chen, JJ | 1 |
| Lee, PL | 1 |
| Chien, RN | 1 |
| Yang, CC | 1 |
| Lo, GH | 1 |
| Kao, JH | 1 |
| Liu, CJ | 1 |
| Liu, CH | 1 |
| Yan, SL | 1 |
| Bair, MJ | 1 |
| Lin, CY | 1 |
| Su, WW | 1 |
| Chu, CH | 2 |
| Chen, CJ | 1 |
| Tung, SY | 1 |
| Tai, CM | 1 |
| Lin, CW | 1 |
| Lo, CC | 1 |
| Cheng, PN | 1 |
| Chiu, YC | 1 |
| Wang, CC | 3 |
| Cheng, JS | 1 |
| Tsai, WL | 1 |
| Lin, HC | 1 |
| Huang, YH | 1 |
| Yeh, ML | 1 |
| Huang, CF | 1 |
| Hsieh, MH | 2 |
| Huang, JF | 1 |
| Dai, CY | 1 |
| Chung, WL | 1 |
| Chen, CY | 1 |
| Yu, ML | 1 |
| Jin, P | 1 |
| Jiang, J | 3 |
| Zhou, L | 3 |
| Huang, Z | 2 |
| Qin, S | 1 |
| Chen, HN | 1 |
| Peng, L | 1 |
| Li, B | 3 |
| Luo, M | 1 |
| Zhang, T | 5 |
| Ming, H | 1 |
| Ding, N | 1 |
| Xie, N | 1 |
| Gao, W | 2 |
| Zhang, W | 5 |
| Nice, EC | 1 |
| Wei, Y | 3 |
| Huang, C | 1 |
| Azit, NA | 3 |
| Sahran, S | 3 |
| Meng, LV | 3 |
| Subramaniam, MK | 3 |
| Mokhtar, S | 3 |
| Nawi, AM | 3 |
| Lin, H | 2 |
| Yiu, DC | 1 |
| Chin, S | 1 |
| Liu, K | 1 |
| Yip, TC | 1 |
| Yuan, B | 1 |
| Ma, J | 1 |
| Wang, J | 9 |
| Hao, J | 1 |
| Zeng, RW | 1 |
| Yong, JN | 1 |
| Tan, DJH | 1 |
| Fu, CE | 1 |
| Lim, WH | 1 |
| Xiao, J | 2 |
| Chan, KE | 1 |
| Tan, C | 1 |
| Goh, XL | 1 |
| Chee, D | 1 |
| Syn, N | 1 |
| Tan, EX | 1 |
| Muthiah, MD | 1 |
| Ng, CH | 1 |
| Tamaki, N | 1 |
| Lee, SW | 1 |
| Kim, BK | 1 |
| Nguyen, MH | 1 |
| Loomba, R | 2 |
| Huang, DQ | 1 |
| Meng, J | 2 |
| Han, J | 1 |
| Wang, X | 9 |
| An, H | 1 |
| Qin, L | 1 |
| Zhong, W | 1 |
| Yang, C | 2 |
| Liu, H | 5 |
| Sun, T | 1 |
| Cheng, L | 1 |
| Deepak, RNVK | 1 |
| Wang, G | 1 |
| Meng, Z | 1 |
| Tao, L | 1 |
| Xie, M | 1 |
| Chi, W | 1 |
| Zhang, Y | 12 |
| Yang, M | 1 |
| Liao, Y | 2 |
| Chen, R | 3 |
| Liang, Y | 1 |
| Zhang, J | 7 |
| Huang, Y | 3 |
| Wang, W | 2 |
| Guo, Z | 3 |
| Lin, JD | 1 |
| Rennert, C | 1 |
| Thimme, R | 1 |
| Zhang, Q | 4 |
| Xiong, L | 1 |
| Wei, T | 1 |
| Liu, Q | 2 |
| Yan, L | 1 |
| Chen, J | 5 |
| Dai, L | 1 |
| Shi, L | 2 |
| Yang, J | 1 |
| Roessler, S | 1 |
| Liu, L | 5 |
| Chu, PT | 1 |
| Chuang, TJ | 1 |
| Huang, SH | 1 |
| Wu, TH | 2 |
| Huang, WC | 1 |
| Cheng, Y | 2 |
| Zhan, P | 1 |
| Lu, J | 3 |
| Lu, Y | 2 |
| Luo, C | 1 |
| Cen, X | 1 |
| Wang, F | 3 |
| Xie, C | 1 |
| Yin, Z | 2 |
| Yao, HJ | 1 |
| Li, JC | 1 |
| Zhao, BQ | 1 |
| Wang, YA | 1 |
| Zhang, YG | 1 |
| Li, W | 3 |
| Mang, Y | 1 |
| Gao, Y | 4 |
| Dong, Y | 2 |
| Zhu, J | 5 |
| Ran, J | 1 |
| Zhang, S | 6 |
| Khajeh, E | 1 |
| Aminizadeh, E | 1 |
| Moghadam, AD | 1 |
| Ramouz, A | 1 |
| Klotz, R | 1 |
| Golriz, M | 1 |
| Merle, U | 1 |
| Springfeld, C | 1 |
| Chang, DH | 1 |
| Longerich, T | 1 |
| Büchler, MW | 1 |
| Mehrabi, A | 1 |
| Li, H | 8 |
| Zhang, L | 4 |
| Yang, F | 1 |
| Zhao, R | 1 |
| Li, X | 13 |
| Ghosh, A | 1 |
| Ghosh, AK | 1 |
| Zaman, A | 1 |
| Das, PK | 1 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Yan, K | 1 |
| Li, C | 3 |
| Zheng, C | 1 |
| Xiao, Y | 2 |
| He, D | 1 |
| Zhao, F | 2 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Li, J | 13 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 1 |
| Feng, C | 1 |
| Wang, Z | 2 |
| Hu, X | 3 |
| Shen, Y | 1 |
| Hu, D | 1 |
| Chen, H | 2 |
| Wu, X | 2 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 2 |
| Yang, X | 7 |
| Wang, H | 6 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 4 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 1 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 2 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Meng, Y | 2 |
| Dong, G | 3 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 2 |
| Cui, JF | 2 |
| Ren, ZG | 2 |
| Chen, RX | 2 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Geng, Y | 1 |
| Basit, A | 1 |
| Miao, T | 1 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Li, S | 2 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 3 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 3 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 1 |
| Wang, C | 6 |
| Zhao, W | 2 |
| Xia, X | 1 |
| Jiang, Y | 2 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 2 |
| Mo, J | 1 |
| Huang, T | 3 |
| Zhu, Q | 1 |
| Wang, S | 3 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 3 |
| Frew, R | 1 |
| Guo, X | 3 |
| Gong, Q | 2 |
| Borowiec, J | 1 |
| Han, S | 2 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 2 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Song, M | 1 |
| Chen, C | 1 |
| Huang, Q | 2 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 5 |
| Fang, L | 2 |
| Xie, CL | 1 |
| Yang, S | 3 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 4 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 1 |
| Wang, B | 1 |
| Xie, S | 2 |
| Deng, W | 1 |
| Wu, D | 4 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 2 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Xu, C | 3 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 2 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Huo, RR | 1 |
| Liang, JR | 1 |
| He, FY | 1 |
| Xu, BR | 1 |
| Ma, L | 1 |
| Yuan, WP | 1 |
| Dogru, T | 1 |
| Kırık, A | 1 |
| Sonmez, A | 1 |
| Vilar-Gomez, E | 4 |
| Chalasani, N | 3 |
| Luo, CS | 1 |
| Lin, Y | 1 |
| Zhou, WP | 1 |
| Shi, J | 1 |
| Park, D | 1 |
| Sun, R | 1 |
| Zhai, R | 1 |
| Miao, W | 1 |
| Jinakote, M | 1 |
| Ontawong, A | 1 |
| Soodvilai, S | 1 |
| Pimta, J | 1 |
| Pasachan, T | 1 |
| Chatsudthipong, V | 1 |
| Srimaroeng, C | 1 |
| Zhang, KF | 1 |
| Guo, J | 2 |
| Huang, YY | 1 |
| Huang, TR | 1 |
| Ghanim, AMH | 1 |
| El-Kader, EMA | 1 |
| Bort, A | 1 |
| Sánchez, BG | 1 |
| de Miguel, I | 1 |
| Mateos-Gómez, PA | 1 |
| Diaz-Laviada, I | 1 |
| Broadhurst, PJ | 1 |
| Hart, AR | 1 |
| El Shorbagy, S | 1 |
| abuTaleb, F | 1 |
| Labib, HA | 1 |
| Ebian, H | 1 |
| Harb, OA | 1 |
| Mohammed, MS | 1 |
| Rashied, HA | 1 |
| Elbana, KA | 1 |
| Haggag, R | 1 |
| Zhou, W | 1 |
| Ren, M | 1 |
| Xu, F | 3 |
| Calzadilla-Bertot, L | 1 |
| Wong, VW | 1 |
| Castellanos, M | 1 |
| Aller-de la Fuente, R | 1 |
| Eslam, M | 1 |
| Wong, GL | 1 |
| George, J | 2 |
| Romero-Gomez, M | 2 |
| Adams, LA | 1 |
| Kopel, J | 1 |
| Higuchi, K | 1 |
| Ristic, B | 1 |
| Sato, T | 1 |
| Ramachandran, S | 1 |
| Ganapathy, V | 1 |
| Yoshida, J | 1 |
| Ishikawa, T | 1 |
| Endo, Y | 1 |
| Matsumura, S | 1 |
| Ota, T | 1 |
| Mizushima, K | 1 |
| Hirai, Y | 1 |
| Oka, K | 1 |
| Okayama, T | 1 |
| Sakamoto, N | 2 |
| Inoue, K | 1 |
| Kamada, K | 1 |
| Uchiyama, K | 1 |
| Takagi, T | 1 |
| Naito, Y | 1 |
| Itoh, Y | 1 |
| Kaplan, DE | 1 |
| Serper, M | 1 |
| John, BV | 1 |
| Tessiatore, KM | 1 |
| Lerer, R | 1 |
| Mehta, R | 1 |
| Fox, R | 1 |
| Aytaman, A | 1 |
| Baytarian, M | 1 |
| Hunt, K | 1 |
| Albrecht, J | 1 |
| Taddei, TH | 1 |
| Qi, L | 1 |
| Lin, YR | 1 |
| Wang, GC | 1 |
| Li, JQ | 1 |
| Yu, JM | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 3 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Huang, W | 1 |
| Cui, Y | 3 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Chen, Y | 4 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 4 |
| Ma, Q | 1 |
| Zhang, E | 1 |
| Xue, F | 2 |
| Deng, L | 1 |
| Yan, Z | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 2 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 1 |
| Ren, Y | 2 |
| Li, P | 2 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, YS | 1 |
| Zhou, X | 7 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 2 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 4 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Li, M | 1 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 2 |
| Huang, H | 1 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 2 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 2 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 2 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Cheng, J | 3 |
| Kong, X | 1 |
| Yang, T | 2 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 2 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 4 |
| Song, Y | 1 |
| Zhu, C | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 3 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 2 |
| Luo, X | 2 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 1 |
| Qi, Y | 2 |
| Cai, X | 2 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 2 |
| Kuang, Y | 1 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Xi, J | 1 |
| Chen, W | 3 |
| Zhang, F | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Huang, J | 3 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 2 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 3 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 3 |
| Tan, H | 2 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Ma, S | 2 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Ye, C | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 2 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 2 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 2 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 3 |
| Qi, MC | 1 |
| Chang, CC | 2 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 3 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 4 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 4 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 3 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 2 |
| Gao, R | 2 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Wei, L | 2 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 3 |
| Wang, T | 2 |
| Li, Q | 5 |
| Cao, T | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 2 |
| Hou, G | 1 |
| Cui, J | 2 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 2 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 2 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Jin, Z | 1 |
| Jia, BX | 1 |
| Tan, LD | 1 |
| Chen, QM | 1 |
| Liu, YH | 1 |
| Kao, TY | 1 |
| Hsieh, TH | 1 |
| Kao, CC | 1 |
| Chuang, PH | 1 |
| Kao, JT | 1 |
| Harreiter, J | 1 |
| Just, I | 1 |
| Leutner, M | 1 |
| Bastian, M | 1 |
| Brath, H | 1 |
| Schelkshorn, C | 1 |
| Klepochova, R | 1 |
| Krššák, M | 1 |
| Kautzky-Willer, A | 1 |
| Di Matteo, S | 1 |
| Nevi, L | 1 |
| Overi, D | 1 |
| Landolina, N | 1 |
| Faccioli, J | 1 |
| Giulitti, F | 1 |
| Napoletano, C | 1 |
| Oddi, A | 1 |
| Marziani, AM | 1 |
| Costantini, D | 1 |
| De Rose, AM | 1 |
| Melandro, F | 1 |
| Bragazzi, MC | 1 |
| Grazi, GL | 1 |
| Berloco, PB | 1 |
| Giuliante, F | 1 |
| Donato, G | 1 |
| Moretta, L | 1 |
| Carpino, G | 1 |
| Cardinale, V | 1 |
| Gaudio, E | 1 |
| Alvaro, D | 1 |
| Cho, WR | 1 |
| Tsai, MY | 1 |
| Chou, CK | 1 |
| Liu, YW | 1 |
| Wu, YJ | 1 |
| Lin, MT | 1 |
| Chen, KD | 1 |
| Chuang, CH | 1 |
| Huang, PY | 1 |
| Hu, TH | 1 |
| Tsai, MC | 1 |
| Pinyopornpanish, K | 2 |
| Leerapun, A | 1 |
| Chattipakorn, N | 1 |
| Gou, S | 1 |
| Qiu, L | 1 |
| Yang, Q | 2 |
| Zhai, W | 1 |
| Harati, R | 1 |
| Vandamme, M | 1 |
| Blanchet, B | 1 |
| Bardin, C | 1 |
| Praz, F | 1 |
| Hamoudi, RA | 1 |
| Desbois-Mouthon, C | 1 |
| Xiao, H | 1 |
| Elsayed, M | 1 |
| Wagstaff, W | 1 |
| Behbahani, K | 1 |
| Villalobos, A | 1 |
| Bercu, Z | 1 |
| Majdalany, BS | 1 |
| Akce, M | 1 |
| Schuster, DM | 1 |
| Mao, H | 1 |
| Kokabi, N | 1 |
| Xu, H | 1 |
| Sui, C | 1 |
| Cha, JH | 1 |
| Yan, M | 1 |
| Cao, N | 1 |
| Ye, P | 1 |
| Yan, X | 1 |
| Yang, WH | 1 |
| Xia, L | 1 |
| Geng, W | 1 |
| Xu, D | 1 |
| Zhong, C | 1 |
| Xia, Q | 2 |
| Zhou, P | 1 |
| Zhang, R | 2 |
| Yao, RR | 1 |
| Li, JH | 1 |
| Zheng, QD | 1 |
| Zhang, HH | 1 |
| Cheng, YN | 1 |
| Gong, FL | 1 |
| Cao, ZQ | 1 |
| Yu, LG | 1 |
| Guo, XL | 1 |
| Zeng, Z | 1 |
| Jia, X | 3 |
| Liang, M | 2 |
| Shi, B | 2 |
| Yi, G | 4 |
| Casadei Gardini, A | 2 |
| Faloppi, L | 3 |
| De Matteis, S | 2 |
| Foschi, FG | 3 |
| Silvestris, N | 2 |
| Tovoli, F | 1 |
| Palmieri, V | 1 |
| Marisi, G | 3 |
| Brunetti, O | 2 |
| Vespasiani-Gentilucci, U | 2 |
| Perrone, G | 1 |
| Valgiusti, M | 1 |
| Granato, AM | 2 |
| Ercolani, G | 2 |
| Negrini, G | 1 |
| Tamburini, E | 2 |
| Aprile, G | 1 |
| Passardi, A | 1 |
| Santini, D | 2 |
| Cascinu, S | 3 |
| Frassineti, GL | 3 |
| Scartozzi, M | 3 |
| Abdelmonsif, DA | 1 |
| Sultan, AS | 1 |
| El-Hadidy, WF | 1 |
| Abdallah, DM | 1 |
| Rogalska, A | 2 |
| Bukowska, B | 1 |
| Marczak, A | 2 |
| Dogan Turacli, I | 1 |
| Candar, T | 1 |
| Yuksel, BE | 1 |
| Demirtas, S | 1 |
| Jiang, Z | 1 |
| Del Campo, JA | 1 |
| García-Valdecasas, M | 1 |
| Gil-Gómez, A | 1 |
| Gallego, P | 1 |
| Ampuero, J | 1 |
| Gallego-Durán, R | 1 |
| Pastor, H | 1 |
| Grande, L | 1 |
| Padillo, FJ | 1 |
| Muntané, J | 1 |
| DeWaal, D | 1 |
| Nogueira, V | 1 |
| Terry, AR | 1 |
| Patra, KC | 1 |
| Jeon, SM | 1 |
| Guzman, G | 1 |
| Au, J | 1 |
| Long, CP | 1 |
| Antoniewicz, MR | 1 |
| Hay, N | 1 |
| Kang, WH | 1 |
| Tak, E | 1 |
| Hwang, S | 1 |
| Song, GW | 1 |
| Jwa, E | 1 |
| Lee, YJ | 1 |
| Kim, KH | 1 |
| Ahn, CS | 1 |
| Moon, DB | 1 |
| Ha, TY | 1 |
| Jung, DH | 1 |
| Park, GC | 1 |
| Lee, KJ | 1 |
| Kim, N | 1 |
| Lee, SG | 1 |
| Yang, L | 1 |
| Tseng, CH | 1 |
| Murff, HJ | 1 |
| Roumie, CL | 1 |
| Greevy, RA | 1 |
| Hackstadt, AJ | 1 |
| McGowan, LED | 1 |
| Hung, AM | 1 |
| Grijalva, CG | 1 |
| Griffin, MR | 1 |
| Feng, Y | 1 |
| Huang, X | 1 |
| Wu, S | 1 |
| Singh, MK | 1 |
| Das, BK | 2 |
| Choudhary, S | 1 |
| Gupta, D | 1 |
| Patil, UK | 1 |
| Lin, X | 1 |
| Gao, D | 1 |
| Ren, Z | 1 |
| de Oliveira, S | 1 |
| Houseright, RA | 1 |
| Graves, AL | 1 |
| Golenberg, N | 1 |
| Korte, BG | 1 |
| Miskolci, V | 1 |
| Huttenlocher, A | 1 |
| Zhang, C | 1 |
| Sheng, L | 1 |
| Zheng, G | 1 |
| Qiu, Z | 2 |
| Schulte, L | 1 |
| Scheiner, B | 1 |
| Voigtländer, T | 1 |
| Koch, S | 1 |
| Schweitzer, N | 1 |
| Marhenke, S | 1 |
| Ivanyi, P | 1 |
| Manns, MP | 1 |
| Rodt, T | 1 |
| Hinrichs, JB | 1 |
| Weinmann, A | 1 |
| Pinter, M | 1 |
| Vogel, A | 1 |
| Kirstein, MM | 1 |
| Sabry, D | 1 |
| Abdelaleem, OO | 1 |
| El Amin Ali, AM | 1 |
| Mohammed, RA | 1 |
| Abdel-Hameed, ND | 1 |
| Hassouna, A | 1 |
| Khalifa, WA | 1 |
| Young, CKJ | 1 |
| Young, MJ | 1 |
| Ferretti, AC | 1 |
| Hidalgo, F | 1 |
| Tonucci, FM | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Larocca, MC | 1 |
| Favre, C | 1 |
| Scarpi, E | 2 |
| La Barba, G | 1 |
| Bandini, E | 1 |
| Ghetti, M | 1 |
| Cravero, P | 1 |
| Gramantieri, L | 1 |
| Cucchetti, A | 1 |
| Casadei-Gardini, A | 1 |
| Wang, CP | 1 |
| Kuhn, J | 1 |
| Shah, DP | 1 |
| Schmidt, S | 1 |
| Lam, YF | 1 |
| MacCarthy, D | 1 |
| Tenner, L | 1 |
| Ramirez, AG | 1 |
| Maehara, O | 1 |
| Ohnishi, S | 1 |
| Asano, A | 1 |
| Suda, G | 1 |
| Natsuizaka, M | 1 |
| Nakagawa, K | 1 |
| Takeda, H | 1 |
| Choukimath, SM | 1 |
| Gadad, PC | 1 |
| Vuppalanchi, R | 1 |
| Desai, AP | 1 |
| Gawrieh, S | 1 |
| Ghabril, M | 1 |
| Saxena, R | 1 |
| Cummings, OW | 1 |
| Kapoor, S | 1 |
| Chaiteerakij, R | 3 |
| Harmsen, WS | 3 |
| Ryu, E | 1 |
| Roberts, RO | 2 |
| Olson, JE | 2 |
| Therneau, TM | 3 |
| Roberts, LR | 3 |
| Fujita, T | 1 |
| Saito, T | 1 |
| Chiba, T | 1 |
| Yuki, K | 1 |
| Zen, Y | 1 |
| Oshima, M | 1 |
| Koide, S | 1 |
| Motoyama, T | 1 |
| Ogasawara, S | 1 |
| Suzuki, E | 1 |
| Ooka, Y | 1 |
| Tawada, A | 1 |
| Tada, M | 1 |
| Kanai, F | 1 |
| Takiguchi, Y | 1 |
| Iwama, A | 1 |
| Yokosuka, O | 1 |
| Yang, W | 1 |
| Wu, F | 1 |
| Yu, L | 1 |
| Tang, L | 1 |
| Qiu, B | 1 |
| Zou, D | 1 |
| Tajima, K | 1 |
| Nakamura, A | 1 |
| Shirakawa, J | 1 |
| Togashi, Y | 1 |
| Orime, K | 1 |
| Sato, K | 1 |
| Inoue, H | 1 |
| Kaji, M | 1 |
| Sakamoto, E | 1 |
| Ito, Y | 1 |
| Aoki, K | 1 |
| Nagashima, Y | 1 |
| Atsumi, T | 1 |
| Terauchi, Y | 1 |
| Xian, L | 1 |
| Yuan, T | 2 |
| Hong, J | 1 |
| He, L | 1 |
| Cai, B | 1 |
| Tan, X | 2 |
| Hu, H | 1 |
| Jing, X | 2 |
| Harris, K | 1 |
| Smith, L | 1 |
| Kim, EH | 2 |
| Cho, CK | 1 |
| Jung, WG | 2 |
| Jeong, YK | 1 |
| Lin, F | 1 |
| Wen, T | 1 |
| Wu, GY | 2 |
| Doycheva, I | 1 |
| Guo, Y | 1 |
| Cheng, W | 1 |
| Yamamoto, T | 1 |
| Miyoshi, H | 2 |
| Kato, K | 1 |
| Iwama, H | 2 |
| Maeda, E | 1 |
| Sakamoto, T | 2 |
| Fujita, K | 2 |
| Toyota, Y | 1 |
| Tani, J | 2 |
| Nomura, T | 2 |
| Mimura, S | 1 |
| Morishita, A | 2 |
| Kobara, H | 1 |
| Mori, H | 1 |
| Yoneyama, H | 2 |
| Deguchi, A | 1 |
| Himoto, T | 1 |
| Kurokohchi, K | 1 |
| Okano, K | 1 |
| Suzuki, Y | 1 |
| Murao, K | 1 |
| Masaki, T | 2 |
| Hagberg, KW | 1 |
| McGlynn, KA | 1 |
| Sahasrabuddhe, VV | 1 |
| Jick, S | 1 |
| Hermann, PC | 1 |
| Sancho, P | 1 |
| Cañamero, M | 1 |
| Martinelli, P | 1 |
| Madriles, F | 1 |
| Michl, P | 1 |
| Gress, T | 1 |
| de Pascual, R | 1 |
| Gandia, L | 1 |
| Guerra, C | 1 |
| Barbacid, M | 1 |
| Wagner, M | 1 |
| Vieira, CR | 1 |
| Aicher, A | 1 |
| Real, FX | 1 |
| Heeschen, C | 1 |
| Hsieh, SC | 1 |
| Tsai, JP | 1 |
| Yang, SF | 1 |
| Tang, MJ | 1 |
| Hsieh, YH | 1 |
| Ling, S | 3 |
| Tian, Y | 4 |
| Jia, K | 1 |
| Feng, T | 2 |
| Hou, Z | 2 |
| Qu, H | 1 |
| Long, XD | 1 |
| Lu, TF | 1 |
| Zhang, WW | 1 |
| Liu, YX | 1 |
| Cui, XL | 1 |
| Dai, HJ | 1 |
| Bhat, M | 1 |
| Schleck, CD | 1 |
| Yang, JD | 2 |
| Giama, NH | 1 |
| Gores, GJ | 2 |
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Indraccolo, S | 1 |
| Randon, G | 1 |
| Zulato, E | 1 |
| Nardin, M | 1 |
| Aliberti, C | 1 |
| Pomerri, F | 1 |
| Casarin, A | 1 |
| Nicoletto, MO | 1 |
| Chen, CI | 1 |
| Kuan, CF | 1 |
| Fang, YA | 1 |
| Liu, SH | 1 |
| Liu, JC | 1 |
| Wu, LL | 1 |
| Chang, CJ | 1 |
| Yang, HC | 1 |
| Hwang, J | 1 |
| Miser, JS | 1 |
| Wu, SY | 1 |
| Lv, Q | 1 |
| Zhen, Q | 1 |
| Goswami, R | 1 |
| Obara, A | 1 |
| Fujita, Y | 1 |
| Abudukadier, A | 1 |
| Fukushima, T | 1 |
| Oguri, Y | 1 |
| Ogura, M | 1 |
| Harashima, S | 1 |
| Hosokawa, M | 1 |
| Inagaki, N | 1 |
| Ohno, T | 1 |
| Shimizu, M | 1 |
| Shirakami, Y | 1 |
| Baba, A | 1 |
| Kochi, T | 1 |
| Tsurumi, H | 1 |
| Tanaka, T | 1 |
| Moriwaki, H | 1 |
| Noureddin, M | 1 |
| Rinella, ME | 1 |
| Lin, CM | 1 |
| Huang, HL | 1 |
| Chu, FY | 1 |
| Fan, HC | 1 |
| Chen, HA | 1 |
| Chu, DM | 1 |
| Wu, LW | 1 |
| Chen, WL | 1 |
| Lin, SH | 1 |
| Ho, SY | 1 |
| Kumar, CS | 1 |
| Raja, MD | 1 |
| Sundar, DS | 1 |
| Gover Antoniraj, M | 1 |
| Ruckmani, K | 1 |
| Bosetti, C | 1 |
| Franchi, M | 1 |
| Nicotra, F | 1 |
| Asciutto, R | 1 |
| Merlino, L | 1 |
| La Vecchia, C | 1 |
| Corrao, G | 1 |
| Hernanda, PY | 1 |
| Bramer, WM | 1 |
| Peppelenbosch, MP | 1 |
| van Luijk, J | 1 |
| Pan, Q | 1 |
| Chen, HH | 1 |
| Lin, MC | 1 |
| Muo, CH | 1 |
| Yeh, SY | 1 |
| Sung, FC | 1 |
| Kao, CH | 1 |
| Peng, YF | 1 |
| Ni, HM | 1 |
| Shi, YH | 1 |
| Ding, WX | 1 |
| Fan, J | 1 |
| Cauchy, F | 2 |
| Mebarki, M | 2 |
| Albuquerque, M | 2 |
| Laouirem, S | 2 |
| Rautou, PE | 2 |
| Soubrane, O | 2 |
| Raymond, E | 1 |
| Bedossa, P | 2 |
| Paradis, V | 3 |
| Hsu, CC | 2 |
| Wu, LC | 1 |
| Hsia, CY | 1 |
| Yin, PH | 1 |
| Chi, CW | 1 |
| Yeh, TS | 1 |
| Lee, HC | 1 |
| Traussnigg, S | 1 |
| Kienbacher, C | 1 |
| Halilbasic, E | 1 |
| Rechling, C | 1 |
| Kazemi-Shirazi, L | 1 |
| Hofer, H | 1 |
| Munda, P | 1 |
| Trauner, M | 1 |
| Lim, JS | 1 |
| Yoo, HJ | 1 |
| Seo, YS | 2 |
| Han, CJ | 2 |
| Park, SC | 1 |
| Kay, CS | 1 |
| Kim, M | 1 |
| Jang, HS | 1 |
| Chang, AR | 1 |
| Gandhy, SU | 1 |
| Imanirad, P | 1 |
| Jin, UH | 1 |
| Nair, V | 1 |
| Hedrick, E | 1 |
| Corton, JC | 1 |
| Kim, K | 1 |
| Safe, S | 1 |
| Berger, E | 1 |
| Vega, N | 1 |
| Weiss-Gayet, M | 1 |
| Géloën, A | 1 |
| Masi, G | 1 |
| Vivaldi, C | 1 |
| Tamberi, S | 1 |
| Tenti, E | 1 |
| Ricca Rosellini, S | 1 |
| Ulivi, P | 1 |
| Nanni, O | 1 |
| Jo, W | 1 |
| Yu, ES | 1 |
| Chang, M | 1 |
| Park, HK | 1 |
| Choi, HJ | 2 |
| Ryu, JE | 1 |
| Jang, JJ | 1 |
| Son, WC | 1 |
| Deng, M | 1 |
| Fu, X | 1 |
| Honda, M | 1 |
| Shirasaki, T | 1 |
| Terashima, T | 1 |
| Kawaguchi, K | 1 |
| Nakamura, M | 1 |
| Oishi, N | 1 |
| Shimakami, T | 1 |
| Okada, H | 1 |
| Arai, K | 1 |
| Yamashita, T | 2 |
| Sakai, Y | 1 |
| Mizukoshi, E | 1 |
| Kaneko, S | 1 |
| Cao, M | 2 |
| You, A | 2 |
| Gao, J | 2 |
| Fang, F | 2 |
| Song, T | 2 |
| DePeralta, DK | 1 |
| Ghoshal, S | 1 |
| Schmidt, B | 1 |
| Lauwers, GY | 1 |
| Lanuti, M | 1 |
| Chung, RT | 1 |
| Tanabe, KK | 1 |
| Fuchs, BC | 1 |
| Shen, C | 2 |
| Ka, SO | 1 |
| Kim, SJ | 1 |
| Kim, JH | 1 |
| Park, BH | 1 |
| Park, JH | 1 |
| Zuo, B | 1 |
| Yin, H | 1 |
| Elkrief, L | 1 |
| Sarin, S | 1 |
| Valla, D | 1 |
| Moreau, R | 1 |
| Sliwinska, A | 1 |
| Kasznicki, J | 1 |
| Drzewoski, J | 1 |
| Stiefelhagen, P | 1 |
| Kim, YJ | 2 |
| Suh, KS | 1 |
| Kim, SB | 1 |
| Kang, SH | 1 |
| Tchoe, HJ | 1 |
| Park, CM | 1 |
| Jo, AJ | 1 |
| Kim, HJ | 1 |
| Choi, JA | 1 |
| Polak, MN | 1 |
| Ko, MJ | 1 |
| Tang, B | 1 |
| Luo, N | 1 |
| Han, Z | 1 |
| Liang, R | 1 |
| Oura, K | 1 |
| Tadokoro, T | 1 |
| Ma, SJ | 1 |
| Zheng, YX | 1 |
| Zhou, PC | 1 |
| Xiao, YN | 1 |
| Tan, HZ | 1 |
| Peng, C | 1 |
| Shen, B | 1 |
| Zhu, Z | 1 |
| Xu, N | 1 |
| Li, T | 1 |
| Xie, J | 1 |
| Zhou, YY | 1 |
| Zhu, GQ | 1 |
| Liu, T | 1 |
| Zheng, JN | 1 |
| Cheng, Z | 1 |
| Zou, TT | 1 |
| Braddock, M | 1 |
| Fu, SW | 1 |
| Zheng, MH | 1 |
| Chan, KM | 1 |
| Kuo, CF | 1 |
| Hsu, JT | 1 |
| Chiou, MJ | 1 |
| Wang, YC | 1 |
| Lee, CF | 1 |
| Wu, TJ | 1 |
| Chou, HS | 1 |
| Lee, WC | 1 |
| Furusawa, Y | 1 |
| Uzawa, A | 1 |
| Sai, S | 1 |
| Leporq, B | 1 |
| Lambert, S | 1 |
| Bourgoin, P | 1 |
| Van Beers, BE | 1 |
| Faivre, S | 1 |
| Song, L | 1 |
| Fan, N | 1 |
| Ono, M | 1 |
| Sawada, K | 1 |
| Okumura, T | 1 |
| Tsai, HH | 1 |
| Lai, HY | 1 |
| Chen, YC | 1 |
| Huang, HS | 1 |
| Liu, HS | 1 |
| Tsai, YS | 1 |
| Wang, JM | 1 |
| Kasmari, AJ | 1 |
| Welch, A | 1 |
| Liu, G | 1 |
| Leslie, D | 1 |
| McGarrity, T | 1 |
| Riley, T | 1 |
| Donadon, V | 3 |
| Balbi, M | 3 |
| Casarin, P | 2 |
| Vario, A | 1 |
| Alberti, A | 1 |
| Zanette, G | 2 |
| Hassan, MM | 1 |
| Curley, SA | 1 |
| Kaseb, A | 1 |
| Davila, M | 1 |
| Abdalla, EK | 1 |
| Javle, M | 1 |
| Moghazy, DM | 1 |
| Lozano, RD | 1 |
| Abbruzzese, JL | 1 |
| Vauthey, JN | 1 |
| Mas, MD | 1 |
| Nicolucci, A | 1 |
| Zhou, K | 1 |
| Bellenguez, C | 1 |
| Spencer, CC | 1 |
| Bennett, AJ | 1 |
| Coleman, RL | 1 |
| Tavendale, R | 1 |
| Hawley, SA | 1 |
| Donnelly, LA | 1 |
| Schofield, C | 1 |
| Groves, CJ | 1 |
| Burch, L | 1 |
| Carr, F | 1 |
| Strange, A | 1 |
| Freeman, C | 1 |
| Blackwell, JM | 1 |
| Bramon, E | 1 |
| Brown, MA | 1 |
| Casas, JP | 1 |
| Corvin, A | 1 |
| Craddock, N | 1 |
| Deloukas, P | 1 |
| Dronov, S | 1 |
| Duncanson, A | 1 |
| Edkins, S | 1 |
| Gray, E | 1 |
| Hunt, S | 1 |
| Jankowski, J | 1 |
| Langford, C | 1 |
| Markus, HS | 1 |
| Mathew, CG | 1 |
| Plomin, R | 1 |
| Rautanen, A | 1 |
| Sawcer, SJ | 1 |
| Samani, NJ | 1 |
| Trembath, R | 1 |
| Viswanathan, AC | 1 |
| Wood, NW | 1 |
| Harries, LW | 1 |
| Hattersley, AT | 1 |
| Doney, AS | 1 |
| Colhoun, H | 1 |
| Morris, AD | 1 |
| Sutherland, C | 1 |
| Hardie, DG | 1 |
| Peltonen, L | 1 |
| McCarthy, MI | 1 |
| Holman, RR | 1 |
| Palmer, CN | 1 |
| Donnelly, P | 1 |
| Pearson, ER | 1 |
| Lee, MS | 1 |
| Wahlqvist, ML | 1 |
| Tsai, HN | 1 |
| Chang, YH | 1 |
| Huang, YC | 1 |
| Chen, TM | 1 |
| Lin, CC | 1 |
| Huang, PT | 1 |
| Wen, CF | 1 |
| Sozio, MS | 1 |
| Lu, C | 1 |
| Zeng, Y | 1 |
| Liangpunsakul, S | 1 |
| Crabb, DW | 1 |
| Nkontchou, G | 1 |
| Cosson, E | 1 |
| Aout, M | 1 |
| Mahmoudi, A | 1 |
| Bourcier, V | 1 |
| Charif, I | 1 |
| Ganne-Carrie, N | 1 |
| Grando-Lemaire, V | 1 |
| Vicaut, E | 1 |
| Trinchet, JC | 1 |
| Beaugrand, M | 1 |
| Wang, P | 1 |
| Kang, D | 1 |
| Cao, W | 1 |
| Haukeland, JW | 1 |
| Dahl, TB | 1 |
| Yndestad, A | 1 |
| Gladhaug, IP | 1 |
| Løberg, EM | 1 |
| Haaland, T | 1 |
| Konopski, Z | 1 |
| Wium, C | 1 |
| Aasheim, ET | 1 |
| Johansen, OE | 1 |
| Aukrust, P | 1 |
| Halvorsen, B | 1 |
| Birkeland, KI | 1 |
| Petrushev, B | 1 |
| Tomuleasa, C | 1 |
| Soritau, O | 1 |
| Aldea, M | 1 |
| Pop, T | 1 |
| Susman, S | 1 |
| Kacso, G | 1 |
| Berindan, I | 1 |
| Irimie, A | 1 |
| Cristea, V | 1 |
| Bhalla, K | 1 |
| Hwang, BJ | 1 |
| Dewi, RE | 1 |
| Twaddel, W | 1 |
| Goloubeva, OG | 1 |
| Wong, KK | 1 |
| Biswal, S | 1 |
| Girnun, GD | 1 |
| Zhang, ZJ | 1 |
| Zheng, ZJ | 1 |
| Shi, R | 1 |
| Jiang, Q | 1 |
| Kip, KE | 1 |
| Chen, HP | 2 |
| Shieh, JJ | 1 |
| Chen, TT | 1 |
| Lin, JT | 1 |
| Wu, MS | 1 |
| Lin, JH | 1 |
| Brower, V | 1 |
| Hou, M | 1 |
| Shao, X | 1 |
| Xiong, Y | 1 |
| Lu, QJ | 1 |
| Slettedahl, SW | 1 |
| Mettler, TA | 1 |
| Fredericksen, ZS | 1 |
| Kim, WR | 1 |
| Zhao, HC | 1 |
| Yao, SK | 1 |
| Singh, S | 2 |
| Singh, PP | 2 |
| Singh, AG | 1 |
| Murad, MH | 1 |
| Sanchez, W | 1 |
| Carulli, L | 1 |
| Maurantonio, M | 1 |
| Hebbard, L | 1 |
| Baldelli, E | 1 |
| Loria, P | 1 |
| Yuan, L | 1 |
| Ziegler, R | 1 |
| Hamann, A | 1 |
| Kim, YD | 1 |
| Park, KG | 1 |
| Lee, YS | 1 |
| Park, YY | 1 |
| Kim, DK | 1 |
| Nedumaran, B | 1 |
| Jang, WG | 1 |
| Cho, WJ | 1 |
| Ha, J | 1 |
| Lee, IK | 1 |
| Lee, CH | 1 |
| Choi, HS | 1 |
| Anfosso, F | 1 |
| Chomiki, N | 1 |
| Alessi, MC | 1 |
| Vague, P | 1 |
| Juhan-Vague, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patie[NCT03007329] | Phase 4 | 34 participants (Actual) | Interventional | 2017-03-08 | Completed | ||
| Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT04182321] | 60 participants (Actual) | Interventional | 2020-03-13 | Completed | |||
| Celebrex and Metformin for Postoperative Hepatocellular Carcinoma[NCT03184493] | Phase 3 | 200 participants (Anticipated) | Interventional | 2017-06-02 | Recruiting | ||
| Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)[NCT02783469] | 1,915 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone[NCT02733679] | Phase 4 | 27 participants (Actual) | Interventional | 2016-09-29 | Completed | ||
| PRIMARY PREVENTION OF HEPATOCELLULAR CARCINOMA BY METFORMIN IN PATIENTS WITH VIRAL C CIRRHOSIS : PROSPECTIVE MULTICENTER STUDY, RANDOMIZED CONTROL TRIAL. Ancillary Study of the ANRS CO12 CirVir Cohort[NCT02319200] | Phase 3 | 11 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Decision of investigator) | ||
| Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)[NCT00303537] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2004-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
30 reviews available for metformin and Cancer of Liver
| Article | Year |
|---|---|
Effect of metformin on
Topics: Animals; Breast Neoplasms; Carcinoma, Hepatocellular; Colonic Neoplasms; Diabetes Mellitus, Type 2; | 2022 |
Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; Tumor Microenvironment | 2022 |
Recent Insights of Metformin on Hepatocellular Carcinoma (HCC).
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Neoplasms; | 2023 |
The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Neoplasms; Metformin; Odds Ratio | 2022 |
Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.
Topics: Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Humans; Hydroxymethylglutaryl-CoA Reductase Inh | 2023 |
Topics: Humans; Liver Neoplasms; Metformin | 2023 |
Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review.
Topics: Analgesics, Opioid; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Esophag | 2023 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels.
Topics: Adult; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Liver Neoplasms; Metf | 2021 |
Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.
Topics: Animals; Carcinoma, Hepatocellular; Disease Progression; Disease Susceptibility; DNA Damage; Hepatoc | 2021 |
Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2022 |
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients.
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver Neoplasms; Me | 2017 |
Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management.
Topics: Animals; Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resistan | 2018 |
Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Hepatitis C, Chronic; Humans; Hypoglycemic Age | 2013 |
Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD).
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Hepatocytes; Humans; Hypoglycemic Agents; Insu | 2014 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoprevention; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; | 2015 |
Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Liver Neoplasms; Male; Metformin; | 2015 |
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Topics: Anticholesteremic Agents; Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Disease Progre | 2015 |
Diabetes mellitus in patients with cirrhosis: clinical implications and management.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Hypoglycemic Agents; I | 2016 |
Diabetes mellitus and metformin in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Live | 2016 |
Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; Prognosis | 2016 |
Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Metformin; Ri | 2016 |
Epidemiological aspects of neoplasms in diabetes.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Case-Control Studies; Cell Divis | 2010 |
Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Me | 2012 |
Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.
Topics: Algorithms; Carcinoma, Hepatocellular; Chemoprevention; Diabetes Mellitus, Type 2; Humans; Hypoglyce | 2012 |
Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Neoplasms; | 2013 |
Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Confidence Intervals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Age | 2013 |
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.
Topics: Carcinoma, Hepatocellular; Child; Fatty Liver; Humans; Hypoglycemic Agents; Liver Neoplasms; Metform | 2013 |
7 trials available for metformin and Cancer of Liver
| Article | Year |
|---|---|
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; | 2022 |
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-contr
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Me | 2021 |
Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Liver; Liver | 2021 |
[Hepatocellular carcinoma - metformin reduces the risk of type 2 diabetes in a dose-dependent manner].
Topics: Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2013 |
Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.
Topics: Adult; alpha-2-HS-Glycoprotein; Biomarkers; Cross-Sectional Studies; Dose-Response Relationship, Dru | 2012 |
163 other studies available for metformin and Cancer of Liver
| Article | Year |
|---|---|
In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Amygdalin; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogen | 2021 |
Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Forkhead Box Pr | 2021 |
A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Carcinoma, Hepatocellular; Cell Survival; C | 2021 |
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dichloroac | 2021 |
Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase.
Topics: Animals; Cell Count; Drug Resistance, Neoplasm; E2F4 Transcription Factor; Folic Acid Antagonists; G | 2021 |
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Glycemic Control; Humans; Insulin; Liver Neopl | 2022 |
Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application.
Topics: Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Carcinoma, Hepatocellular; Disease Progression; | 2022 |
Metformin exerts anti-tumor effects via Sonic hedgehog signaling pathway by targeting AMPK in HepG2 cells.
Topics: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diab | 2022 |
The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival.
Topics: Carcinoma, Hepatocellular; Child; Diabetes Mellitus, Type 2; Glucose; Humans; Incidence; Liver Cirrh | 2022 |
Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemotherapy, Adjuvant; Gamma Rays; Humans; Li | 2022 |
Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Clustered Regularly Int | 2022 |
Metformin Protects Against Sunitinib-induced Cardiotoxicity: Investigating the Role of AMPK.
Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cardiotoxicity; | 2022 |
Metformin treatment rescues CD8
Topics: Animals; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Immune Checkpoint Inhibitors; Liver; | 2022 |
Role of metformin in the diagnosis, prevention, and treatment of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus, Type 2; Humans; | 2022 |
Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling.
Topics: Animals; Carcinoma, Hepatocellular; Endometrial Hyperplasia; Endometrium; Female; Glucose Transporte | 2022 |
Metformin keeps CD8
Topics: Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Humans; Immunotherapy; Liver Neoplasms; Metfo | 2022 |
Metformin inhibits the development and metastasis of colorectal cancer.
Topics: AMP-Activated Protein Kinases; Animals; Carcinogenesis; Cell Line, Tumor; Colorectal Neoplasms; Huma | 2022 |
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolife | 2022 |
Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diabetes Mellitus, Type 2; Humans; Liver | 2022 |
Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diabetes Melli | 2022 |
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Mellitus; Hepatitis C, C | 2023 |
Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis.
Topics: Adenosine Triphosphate; Carcinoma, Hepatocellular; Cell Line; Humans; Liver Neoplasms; Metformin; Mi | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
Topics: Alkaline Phosphatase; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans | 2022 |
Metformin in patients with hepatocellular carcinoma receiving immunotherapy.
Topics: Carcinoma, Hepatocellular; Humans; Hypoglycemic Agents; Immunotherapy; Liver Neoplasms; Metformin | 2023 |
Twist1-YY1-p300 complex promotes the malignant progression of HCC through activation of miR-9 by forming phase-separated condensates at super-enhancers and relieved by metformin.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplas | 2023 |
Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis.
Topics: AMP-Activated Protein Kinases; Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Transformati | 2023 |
Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; PPAR gamma | 2023 |
The impact of metformin on survival in diabetes patients with operable colorectal cancer: A nationwide retrospective cohort study.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Neoplasms; Metfo | 2023 |
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms | 2023 |
Activated Carbon nanoparticles Loaded with Metformin for Effective Against Hepatocellular Cancer Stem Cells.
Topics: AC133 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Charcoal; Humans; Liver Neoplasms; Metfo | 2023 |
Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Liver Neoplasms; Metfo | 2023 |
Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatectomy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2023 |
Metformin-Loaded Hyaluronic Acid-Derived Carbon Dots for Targeted Therapy against Hepatocellular Carcinoma by Glutamine Metabolic Reprogramming.
Topics: Carbon; Carcinoma, Hepatocellular; Cell Line, Tumor; Glutamine; HEK293 Cells; Humans; Hyaluronan Rec | 2023 |
Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Ne | 2019 |
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin; N | 2019 |
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin; N | 2019 |
Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin | 2019 |
Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis.
Topics: Carcinoma, Hepatocellular; China; Diabetes Mellitus; Disease-Free Survival; Hepatectomy; Humans; Liv | 2020 |
Metformin Induces Oxidative Stress-Mediated Apoptosis without the Blockade of Glycolysis in H4IIE Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Glucos | 2019 |
Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Dru | 2020 |
High affinity of 4-(4-(dimethylamino)styryl)-N-methylpyridinium transport for assessing organic cation drugs in hepatocellular carcinoma cells.
Topics: Biological Transport; Carcinoma, Hepatocellular; Cations; Cell Line, Tumor; Hep G2 Cells; Hepatocyte | 2020 |
Metformin enhances radiosensitivity in hepatocellular carcinoma by inhibition of specificity protein 1 and epithelial-to-mesenchymal transition.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Surv | 2019 |
Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Diethylnitrosa | 2020 |
Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2020 |
An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases.
Topics: Aged; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Cross-Sectional Studies; Fe | 2020 |
Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Hypoxia; Liver Neoplasms; Male; Metformin; Mic | 2020 |
Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Liver Neoplasms; Metf | 2021 |
The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin.
Topics: Aminoimidazole Carboxamide; Carcinoma, Hepatocellular; Citric Acid; Gene Expression Regulation, Neop | 2020 |
Metformin inhibits TGF‑β1‑induced epithelial‑mesenchymal transition and liver metastasis of pancreatic cancer cells.
Topics: Animals; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epithelial-Me | 2020 |
Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Liver Neoplasms; Metf | 2021 |
Novel Albumin Nanoparticle Enhanced the Anti-Insulin-Resistant-Hepatoma Activity of Metformin.
Topics: Animals; Carcinoma, Hepatocellular; Circular Dichroism; Diabetes Mellitus, Type 2; Drug Delivery Sys | 2020 |
Combination therapy with metformin and IL-12 to inhibit the growth of hepatic carcinoma by promoting apoptosis and autophagy in HepG2-bearing mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; | 2020 |
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Di | 2020 |
Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Cholangioc | 2021 |
Metformin leads to accumulation of reactive oxygen species by inhibiting the NFE2L1 expression in human hepatocellular carcinoma cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Carcinoma, Hepatocellular; Gene Expression Reg | 2021 |
Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diabetes Me | 2021 |
Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver Neoplasms; Metformin; Pneumonect | 2021 |
ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Down-Regulation; Female; Humans; Hypoglycemic A | 2021 |
Metformin suppresses interleukin-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
Topics: Animals; Carcinoma, Hepatocellular; Disease Models, Animal; Hippo Signaling Pathway; Interleukin-22; | 2021 |
Activated hepatic stellate cells secrete periostin to induce stem cell-like phenotype of residual hepatocellular carcinoma cells after heat treatment.
Topics: Animals; beta Catenin; Biomarkers; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Glycogen Synt | 2017 |
Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line; Cell | 2018 |
Negative regulation of Sirtuin 1 by AMP-activated protein kinase promotes metformin-induced senescence in hepatocellular carcinoma xenografts.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Proliferation; Cellular Sene | 2017 |
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual | 2017 |
Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Aspirin; beta | 2018 |
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ca | 2018 |
Role of metformin on base excision repair pathway in p53 wild-type H2009 and HepG2 cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; DNA Polymerase I; DNA Repair; Hep G2 Cells; Humans | 2018 |
Metformin inhibits tumorigenesis in HBV-induced hepatocellular carcinoma by suppressing HULC overexpression caused by HBX.
Topics: Carcinoma, Hepatocellular; Cell Transformation, Viral; Female; Hep G2 Cells; Hepatitis B; Hepatitis | 2018 |
Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
Topics: Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Proliferation; C | 2018 |
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells; | 2018 |
Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From
Topics: Aged; Animals; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Chemoprevention; C | 2018 |
Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30).
Topics: Acetyltransferases; Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hep | 2018 |
Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Topics: Aged; Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Diabetes Mellitus, Typ | 2018 |
Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer.
Topics: Aged; Carcinoma, Hepatocellular; Female; Humans; Hypoglycemic Agents; Incidence; Liver Neoplasms; Ma | 2018 |
Metformin reverses stem cell‑like HepG2 sphere formation and resistance to sorafenib by attenuating epithelial‑mesenchymal transformation.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Hep G2 Cells; H | 2018 |
Treatment-damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fibrosis; Growth Dif | 2018 |
Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
Topics: Animals; Animals, Genetically Modified; Carcinoma, Hepatocellular; Cell Polarity; Diet, High-Fat; Di | 2019 |
Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Topics: Adenosine Triphosphate; Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; Cell Line, Tumo | 2019 |
Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Germany; | 2019 |
Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study.
Topics: Anticarcinogenic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Catechin; Cell Line, Tumor | 2019 |
Comparison of HepaRG cells following growth in proliferative and differentiated culture conditions reveals distinct bioenergetic profiles.
Topics: Acetaminophen; Adenosine Triphosphate; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Diff | 2019 |
Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration.
Topics: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Epithelia | 2019 |
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans | 2019 |
Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases.
Topics: Aged; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Healthcare Disparit | 2019 |
Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines.
Topics: AC133 Antigen; AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Carcinoma, Hepatocellular; | 2019 |
Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Carcinoma, Hepatocellular; Diabetes Mellitus, Experimen | 2019 |
Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Liver | 2019 |
Metformin therapy and its anti-neoplastic role in systemic malignancies besides hepatocellular carcinomas.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Neoplasms; | 2013 |
Reply: To PMID 23055147.
Topics: Cholangiocarcinoma; Diabetes Mellitus; Female; Humans; Liver Neoplasms; Male; Metformin | 2013 |
Analyzing risk factors for intrahepatic cholangiocarcinoma.
Topics: Cholangiocarcinoma; Diabetes Mellitus; Female; Humans; Liver Neoplasms; Male; Metformin | 2013 |
Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Cell Proliferation; Flow Cytom | 2013 |
Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, He | 2013 |
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.
Topics: Adipose Tissue, White; Animals; Anticarcinogenic Agents; Carcinogenesis; Carcinoma, Hepatocellular; | 2013 |
Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway.
Topics: AMP-Activated Protein Kinase Kinases; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell | 2013 |
Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Topics: Aminoimidazole Carboxamide; Animals; Carcinoma, Hepatocellular; Cell Survival; Cyclin D1; Cyclin-Dep | 2013 |
Low and high linear energy transfer radiation sensitization of HCC cells by metformin.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug | 2014 |
[Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism].
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Sub | 2013 |
AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell | 2014 |
Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Gene Expres | 2014 |
Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Child; Databases, Factual; Diabete | 2014 |
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Topics: Acinar Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Carcinoma, Pancreatic Ductal; Cell D | 2014 |
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinas | 2014 |
Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells.
Topics: AMP-Activated Protein Kinases; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellu | 2014 |
Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Hep G2 Cells; Hep | 2015 |
Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; G | 2015 |
Metformin does not improve survival in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans | 2014 |
Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergi | 2015 |
Metformin: a modulator of bevacizumab activity in cancer? A case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Cancer risk in HBV patients with statin and metformin use: a population-based cohort study.
Topics: Adult; Cohort Studies; Drug Synergism; Female; Hepatitis B, Chronic; Humans; Hydroxymethylglutaryl-C | 2015 |
AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Hep G2 Cells; | 2015 |
DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells.
Topics: Base Sequence; Cell Line, Tumor; DNA Primers; Humans; Intracellular Signaling Peptides and Proteins; | 2015 |
Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice.
Topics: Adipokines; Animals; Animals, Newborn; Carcinogenesis; Diabetes Mellitus, Experimental; Diethylnitro | 2015 |
Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study.
Topics: Adult; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus; Female; Glycoside Hydrolase Inhibito | 2015 |
Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells).
Topics: Animals; Cell Survival; Drug Delivery Systems; Embryo, Nonmammalian; Ethyldimethylaminopropyl Carbod | 2015 |
Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.
Topics: Aged; Case-Control Studies; Cohort Studies; Confidence Intervals; Databases, Pharmaceutical; Drug Pr | 2015 |
Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia.
Topics: Aged; Asia; Carcinoma, Hepatocellular; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy | 2015 |
Basal Autophagy and Feedback Activation of Akt Are Associated with Resistance to Metformin-Induced Inhibition of Hepatic Tumor Cell Growth.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; H | 2015 |
Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Neo | 2015 |
Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs.
Topics: Adenosine Triphosphate; Apoptosis; Carcinoma, Hepatocellular; Energy Metabolism; Glycolysis; Hep G2 | 2015 |
Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis.
Topics: Aged; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier | 2015 |
Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cell Survival; | 2015 |
Gene Network Analysis of Glucose Linked Signaling Pathways and Their Role in Human Hepatocellular Carcinoma Cell Growth and Survival in HuH7 and HepG2 Cell Lines.
Topics: AMP-Activated Protein Kinase Kinases; Carcinoma, Hepatocellular; Cell Proliferation; Gene Expression | 2015 |
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Resistance, Neopla | 2015 |
Metformin inhibits early stage diethylnitrosamine‑induced hepatocarcinogenesis in rats.
Topics: Adenylate Kinase; Animals; Blotting, Western; Body Weight; Carcinogenesis; Carcinoma, Hepatocellular | 2016 |
Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Carcinoma, Hepatocellular; Cell Hypoxia; | 2016 |
Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Hepatitis B Core | 2016 |
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene E | 2016 |
Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.
Topics: Animals; Biopsy, Needle; Blotting, Western; Carcinoma, Hepatocellular; Cell Transformation, Neoplast | 2016 |
Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Blotting, Western; | 2016 |
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Effects of Epothilone A in Combination with the Antidiabetic Drugs Metformin and Sitagliptin in HepG2 Human Hepatocellular Cancer Cells: Role of Transcriptional Factors NF-κB and p53.
Topics: Antineoplastic Agents; Apoptosis; Benzoxazoles; Carcinoma, Hepatocellular; Dactinomycin; Diabetes Me | 2016 |
[The risk is higher, but why?].
Topics: Carcinoma, Hepatocellular; Diabetes Complications; Humans; Liver Neoplasms; Metformin; Neoplasms; Pa | 2016 |
Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cause of Death; Cohort Studies; Comorbidity; Diabe | 2016 |
Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepato | 2016 |
Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line | 2016 |
Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Hepatectomy; Humans; Hypo | 2017 |
Metformin enhances the radiosensitivity of human liver cancer cells to γ-rays and carbon ion beams.
Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Hepatocellular; DNA Damage; Dose-Response Relat | 2016 |
Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Proliferati | 2017 |
Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cel | 2017 |
A case of liver hemangioma with markedly reduced tumor size after metformin treatment: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Hemangioma; Humans; Liver Neoplasms; Magnetic Resona | 2017 |
Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Hepatocellular; | 2017 |
Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
Topics: Adult; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Hepatitis C; Human | 2017 |
Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Topics: Aged; Carcinoma, Hepatocellular; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hy | 2008 |
Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Hyperins | 2009 |
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Diabetes Complications; Diabetes Melli | 2010 |
Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Chronic Disease; Diabetes Mellitus, Ty | 2010 |
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Hepatocellular; Cell Cycle Proteins; Dia | 2011 |
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Hepatocellular; Cell Cycle Proteins; Dia | 2011 |
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Hepatocellular; Cell Cycle Proteins; Dia | 2011 |
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Hepatocellular; Cell Cycle Proteins; Dia | 2011 |
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.
Topics: Adult; Aged; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I | 2011 |
Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Hepatocellular; Catheter Ablation; | 2011 |
Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell | 2011 |
Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hepatitis C, | 2011 |
Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cel | 2012 |
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; | 2012 |
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Blotting, Western; Carcinoma, Hepatocel | 2013 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair.
Topics: Adenosine Triphosphate; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA | 2012 |
Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway.
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; C | 2012 |
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Case-Control Studies; | 2013 |
Metformin and risk of hepatocellular carcinoma: are statins the missing link?
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Neo | 2013 |
Authors' response: Metformin and risk of hepatocellular carcinoma--a study focused on anti-diabetic agents.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Neo | 2013 |
Metformin modulates insulin post-receptor signaling transduction in chronically insulin-treated Hep G2 cells.
Topics: Carcinoma, Hepatocellular; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Neoplasms; Metform | 2003 |
Effect of ecdysterone on glucose metabolism in vitro.
Topics: Animals; Cell Line, Tumor; Chromans; Dose-Response Relationship, Drug; Ecdysterone; Glucose; Humans; | 2006 |
Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Gluconeogenesis | 2008 |
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.
Topics: Acetates; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cells, Cultured; DNA Probes; Dose-Respons | 1993 |